WO2010048708A1 - System and method for magnetic resonance imaging - Google Patents

System and method for magnetic resonance imaging Download PDF

Info

Publication number
WO2010048708A1
WO2010048708A1 PCT/CA2009/001538 CA2009001538W WO2010048708A1 WO 2010048708 A1 WO2010048708 A1 WO 2010048708A1 CA 2009001538 W CA2009001538 W CA 2009001538W WO 2010048708 A1 WO2010048708 A1 WO 2010048708A1
Authority
WO
WIPO (PCT)
Prior art keywords
magnetic field
mri
pulse sequence
image
polarizing
Prior art date
Application number
PCT/CA2009/001538
Other languages
French (fr)
Inventor
Jamu Alford
Blaine Chronik
Timothy Scholl
Original Assignee
The University Of Western Ontario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Western Ontario filed Critical The University Of Western Ontario
Priority to US13/126,253 priority Critical patent/US9423480B2/en
Publication of WO2010048708A1 publication Critical patent/WO2010048708A1/en
Priority to US15/166,711 priority patent/US10663548B2/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48NMR imaging systems
    • G01R33/54Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/28Details of apparatus provided for in groups G01R33/44 - G01R33/64
    • G01R33/38Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field
    • G01R33/381Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using electromagnets
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/28Details of apparatus provided for in groups G01R33/44 - G01R33/64
    • G01R33/38Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field
    • G01R33/385Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using gradient magnetic field coils
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/445MR involving a non-standard magnetic field B0, e.g. of low magnitude as in the earth's magnetic field or in nanoTesla spectroscopy, comprising a polarizing magnetic field for pre-polarisation, B0 with a temporal variation of its magnitude or direction such as field cycling of B0 or rotation of the direction of B0, or spatially inhomogeneous B0 like in fringe-field MR or in stray-field imaging
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48NMR imaging systems
    • G01R33/54Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5608Data processing and visualization specially adapted for MR, e.g. for feature analysis and pattern recognition on the basis of measured MR data, segmentation of measured MR data, edge contour detection on the basis of measured MR data, for enhancing measured MR data in terms of signal-to-noise ratio by means of noise filtering or apodization, for enhancing measured MR data in terms of resolution by means for deblurring, windowing, zero filling, or generation of gray-scaled images, colour-coded images or images displaying vectors instead of pixels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48NMR imaging systems
    • G01R33/54Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/561Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
    • G01R33/5615Echo train techniques involving acquiring plural, differently encoded, echo signals after one RF excitation, e.g. using gradient refocusing in echo planar imaging [EPI], RF refocusing in rapid acquisition with relaxation enhancement [RARE] or using both RF and gradient refocusing in gradient and spin echo imaging [GRASE]
    • G01R33/5617Echo train techniques involving acquiring plural, differently encoded, echo signals after one RF excitation, e.g. using gradient refocusing in echo planar imaging [EPI], RF refocusing in rapid acquisition with relaxation enhancement [RARE] or using both RF and gradient refocusing in gradient and spin echo imaging [GRASE] using RF refocusing, e.g. RARE
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48NMR imaging systems
    • G01R33/50NMR imaging systems based on the determination of relaxation times, e.g. T1 measurement by IR sequences; T2 measurement by multiple-echo sequences
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48NMR imaging systems
    • G01R33/54Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • GPHYSICS
    • G10MUSICAL INSTRUMENTS; ACOUSTICS
    • G10KSOUND-PRODUCING DEVICES; METHODS OR DEVICES FOR PROTECTING AGAINST, OR FOR DAMPING, NOISE OR OTHER ACOUSTIC WAVES IN GENERAL; ACOUSTICS NOT OTHERWISE PROVIDED FOR
    • G10K9/00Devices in which sound is produced by vibrating a diaphragm or analogous element, e.g. fog horns, vehicle hooters or buzzers

Definitions

  • This specification relates generally to magnetic resonance imaging and more particularly, to a system and method for producing image contrast in magnetic resonance imaging.
  • Nuclear Magnetic Resonance (NMR) Imaging or Magnetic Resonance Imaging (MRI) as it is commonly known, is a non-invasive imaging modality that can produce high resolution, high contrast images of the interior of a subject.
  • MRI involves the interrogation of the nuclear magnetic moments of a sample placed in a strong magnetic field with radio frequency (RF) magnetic fields.
  • RF radio frequency
  • the subject typically a human patient, is placed into the bore of an MRI machine and is subjected to a uniform magnetic field B 0 produced by a polarizing magnet housed within the MRI machine.
  • Radio frequency (RF) pulses generated by RF coils housed within the MRI machine in accordance with a particular localization method, are typically used to scan target tissue of the patient.
  • MRI signals are radiated by excited nuclei in the target tissue in the intervals between consecutive RF pulses and are sensed by the RF coils.
  • gradient magnetic fields are switched rapidly to alter the uniform magnetic field at localized areas thereby allowing spatial localization of MRI signals radiated by selected slices of the target tissue.
  • the sensed MRI signals are in turn digitized and processed to reconstruct images of the target tissue slices using one of many known techniques.
  • the longitudinal magnetization Mz may be rotated, or "tipped" into the x-y plane to produce a net transverse magnetic moment M ⁇ _
  • the excitation magnetic field Bi is terminated, relaxation of the excited spins occurs, with a signal being emitted that effects the magnitude of radiated MRI signals.
  • the emitted signal is received and processed to form an image.
  • the longitudinal magnetization M z relaxes back to its equilibrium.
  • the time constant that describes how the longitudinal magnetization Mz returns to its equilibrium value is commonly referred to as the spin lattice relaxation time T 1 .
  • the spin lattice relaxation time Ti characterizes the time required to reduce the difference between the longitudinal magnetization Mz and its equilibrium longitudinal magnetization value M 0 to zero.
  • the net transverse magnetic moment M X ⁇ also relaxes back to its equilibrium when the excitation magnetic field Bi is terminated.
  • the time constant that describes how the transverse magnetic moment MXY returns to its equilibrium value is commonly referred to as transverse relaxation time or spin- spin relaxation time T 2 .
  • the transverse relaxation time T 2 characterizes the time required to reduce the transverse magnetic moment M X ⁇ to zero.
  • Both the spin lattice relaxation time T 1 and the transverse relaxation time T 2 are tissue specific and vary with concentration of different chemical substances in the tissue as well as with different microstructural features of the tissue. Variations of the spin lattice relaxation time T 1 and/or the transverse relaxation time T 2 from normal can also be indicative of disease or injury.
  • MRI can be used to differentiate tissue types, e.g. muscles from tendons, white matter from gray matter, healthy tissue from pathologic tissue, etc.
  • tissue types e.g. muscles from tendons, white matter from gray matter, healthy tissue from pathologic tissue, etc.
  • MRI techniques There exist many different MRI techniques, the utility of each depending on the particular tissues under examination. Some techniques examine the rate of tissue magnetization, while others measure the amount of bound water or the velocity of blood flow. Often, several MRI techniques are used together to improve tissue identification. In general, the greater the number of identification methods available the better chance of identifying a certain tissue type or pathology.
  • contrast agents or contrast materials may be used to emphasize certain anatomical regions.
  • a Gadolinium chelate injected into a blood vessel will produce enhancement of the vascular system, or the presence and distribution of leaky blood vessels.
  • Iron-loaded stem cells injected into the body and detected by MRI, will allow stem cell migration and implantation in vivo to be tracked.
  • Contrast agents can enhance imaging of target sites or tissues through the complementary processes of accumulation and activation. Accumulation occurs when the local concentration of the contrast agent is increased through metabolic uptake or molecular adhesion leading to localized image enhancement. A growing number of contrast agents are also activatable, their behavior mediated by interaction with a target molecule, such as a specific protein or macromolecule.
  • Contrast agents demonstrating activation are interchangeably called “sensing”, “smart”, or “activatable” contrast agents.
  • Activatable contrast agents are used in MRI studies to improve the specificity of the contrast agent (2). Ideally activatable contrast agents produce no image enhancement in the inactivated state; however, to date, these contrast agents combined with conventional MRI have shown image intensity enhancement in both inactivated and activated states, with relatively modest signal intensity ratios between these two states. [0011] Accordingly, there is a continuing need for improvements in MRI.
  • a method for contrast agent enhanced magnetic resonance imaging (MRI) of a target sample comprising generating a magnetic field shift in a polarizing magnetic field during a relaxation portion of an MRI pulse sequence and thereafter acquiring an MR image.
  • MRI contrast agent enhanced magnetic resonance imaging
  • a method of magnetic resonance imaging comprising subjecting a sample to polarizing magnetic fields of different strengths and acquiring a scan associated with each polarizing magnetic field; and processing the scans to generate selective image contrast of said sample based on the variation of at least one MR property of the sample in response to the different polarizing magnetic field strengths.
  • a magnetic resonance imaging method comprising performing multiple scans of a subject and generating an image for each scan, each scan being conducted utilizing a different polarizing magnetic field; and processing the images to yield an enhanced contrast image, wherein said performing comprises: shifting the polarizing magnetic field of an MRI machine in one direction during a relaxation portion of a first pulse sequence and thereafter acquiring an image; and shifting the polarizing magnetic field of the MRI machine in an opposite direction during a relaxation portion of a second pulse sequence and thereafter acquiring an image.
  • an MRI machine comprising a housing having a bore in which a subject to be imaged is placed; a polarizing electromagnet accommodated by said housing and generating a generally uniform polarizing magnetic field within said bore; pulse generating coils to generate pulses in a sequence to scan the subject; and gradient coils to encode acquired MRI signals, wherein said gradient coils are futher configured to genate a shift in the polarizing magnetic field during a relaxation portion of the sequence.
  • Figure 1 is a schematic block diagram of an MRI system
  • Figure 2 is a cutaway view of an MRI machine forming part of the
  • Figure 3 is a graph of relaxivity as a function of field strength for the activatable contrast agent Vasovist alone (+) or in the presence of human
  • Figure 4 is a schematic of (a) the Ti + sequence and (b) the " resequence of spin-echo pulse sequences where an auxiliary-magnet-induced ⁇ B magnetic field pulse of duration t ⁇ has been used to modify the strength of the static Bo field during a Ti relaxation portion of the sequences;
  • Figure 5 shows (a) an experimental sample and its MRI resulting in (b) a conventional Ti weighted image and (c) a Ti weighted image using the system and method described herein;
  • Figure 6 graphs the sample intensities found in the images shown in Figure 5 (b) and (c);
  • Figure 7 is a schematic of a spin-echo pulse sequence where a gradient coil-induced ⁇ B magnetic field pulse of duration t ⁇ has been used to modify the strength of the static B 0 field during a T 1 relaxation portion of the sequence;
  • Figure 8 shows placement of a target sample offset from the iso- center;
  • Figure 9 shows the current path of a conventional longitudinal (i.e., z-axis) gradient coil
  • Figure 10 shows the current path of the gradient coil shown in Figure 9 modified in accordance with the system and method described herein, when the modified gradient coil is used to generate a varying magnetic field across an imaging region;
  • Figure 11 shows the current path of the modified gradient coil shown in Figure 10, when the modified gradient coil is used to produce a substantially uniform magnetic field across the imaging region;
  • Figure 12 is a graph showing the two magnetic fields that can be generated by the modified gradient coil shown in Figures 10 and 11 plotted as a function of the spatial position within the imaging region with 0 indicating the iso- center;
  • Figure 13 shows the wire pattern and current flow of the modified gradient coil shown in Figure 10;
  • Figure 14 shows the wire pattern and current flow of the modified gradient coil shown in Figure 11 ;
  • Figure 15 shows the wire pattern and current flow of a transverse gradient coil, modified in accordance with the system and method described herein, when the modified gradient coil is used to generate a varying magnetic field across an imaging region;
  • Figure 16 shows the wire pattern and current flow of the modified gradient coil shown in Figure 15, when the modified gradient coil is used to produce a substantially uniform magnetic field across the imaging region;
  • Figure 17 shows a computer simulation of a conventional T 1 weighted image of a tumour over its surrounding interstitial fluid at various concentrations of the activatable contrast agent, Vasovist;
  • Figure 18 shows a computer simulation of a T 1 weighted image of the tumour and surrounding interstitial fluid as shown in Figure 17 obtained with the tumour positioned at the iso-center and using a conventional MRI machine with the z-gradient coil programmed to generate a ⁇ B magnetic field that is linearly varying across the imaging region;
  • Figure 19 shows the ⁇ B magnetic field and tumour position used to obtain the image shown in Figure 18;
  • Figure 20 shows a computer simulation of a T 1 weighted image of the tumour and surrounding interstitial fluid as shown in Figures 17 and 18 obtained with the tumour positioned offset from the iso-center and using a conventional MRI machine with the z-gradient coil programmed to generate a ⁇ B magnetic field that is linearly varying across the imaging region;
  • Figure 21 shows the ⁇ B magnetic field and tumour position used to obtain the image shown in Figure 20;
  • Figure 22 shows a computer simulation of a T 1 weighted image of the tumour and surrounding interstitial fluid as shown in Figures 17, 18 and 19 obtained with the tumour positioned located at the iso-center and using an MRI machine with a modified z-gradient coil programmed to generate a ⁇ B magnetic field that is substantially uniform across the imaging region;
  • Figure 23 shows the ⁇ B magnetic field and tumour position used to obtain the image shown in Figure 22.
  • Embodiments described in the present specification relate to a method and system for magnetic resonance imaging of samples which make use of a dynamically controlled MRI polarizing magnetic field and a contrast agent or endogenous substance that demonstrates a magnetic field-dependent variation in one or more MRI properties.
  • the system and method described herein provide increased specificity in MRI by utilizing an auxiliary magnetic field to modify the strength of the main polarizing magnetic field as a function of time during a relaxation portion of an MRI pulse sequence.
  • an auxiliary magnetic field ⁇ B is applied during a relaxation portion of an MRI pulse sequence.
  • an electromagnetic coil insert ( ⁇ B insert) is incorporated into a conventional MRI machine, to generate a substantially uniform magnetic field, across an imaging region, during a relaxation portion of an MRI pulse sequence.
  • a gradient coil in a conventional MRI machine is programmed to generate a varying magnetic field, across an imaging region, during a relaxation portion of the MRI pulse sequence, with the target sample being placed offset from the iso-center of the MRI machine.
  • a gradient coil is modified to generate a substantially uniform magnetic field, across an imaging region, during a relaxation portion of the MRI pulse sequence.
  • Iso-center refers to a location within an MRI machine where a varying magnetic field generated by a gradient coil is zero.
  • offsetting the target sample from the iso-center allows for the gradient coil induced magnetic field to be non-zero across the target sample.
  • the iso-center typically coincides with the spatial center of a magnet assembly in an MRI machine.
  • Relaxation refers to a return of excited spins to their equilibrium distribution in which there is no transverse magnetization and/or the longitudinal magnetization is at its maximum value and oriented in the direction of the main static magnetic field B 0 generated by the MRI machine. After excitation the transverse magnetization decays toward zero with a characteristic time constant T2, and the longitudinal magnetization returns toward equilibrium with a characteristic time constant Ti.
  • the method and system take advantage of the change in longitudinal relaxivity vs. magnetic field strength, i.e. the relaxivity slope, to produce selective image contrast when a contrast agent binds to a given target molecule.
  • the MRI system 10 comprises an operator console 20, a computer system 40, a system controller 60, a gradient amplifier system 80, an RF coil control circuit 100 and an MRI machine 120.
  • the operator console 20 allows an operator to control the MRI system 10 including the production and display of images.
  • the computer system 40 is responsive to commands generated by the operator console 120 and generates images for display.
  • the system controller 60 communicates with the operator console 20, the computer system 40, the gradient amplifier system 80 and the RF coil control circuit 100 and orchestrates the acquisition of images in response to commands generated by the operator console 20.
  • the MRI machine 120 communicates with the gradient amplifier system 80 and the RF coil control circuit 100.
  • the operator console 20 comprises an input device 22, a control panel 24 coupled to the input device 22, and a display 26.
  • the input device 22 can comprise a mouse, joystick, keyboard, trackball, touch screen, light wand, voice control, or similar such device, and may be used for interactive geometry prescription.
  • the operator console 20 communicates with the computer system 40 over a data communications link 28 thereby to enable an operator to control the production and presentation of images on the display 26.
  • the computer system 40 comprises a number of modules, which communicate with each other through a backplane 42. As can be seen, the modules of computer system 40 comprise an image processor module 44, a CPU module 46, and a memory buffer 48, known in the art as a frame buffer for storing image data arrays.
  • the computer system 40 is linked to a disk storage 50 and a tape drive 52 for storage of image data and programs.
  • the computer system 40 communicates with the system controller 60 over a high-speed serial data communications link 54.
  • the system controller 60 also comprises a number of modules, which communicate with each other through a backplane 62.
  • the modules of system controller 60 comprise a CP module 64, a pulse generator module 66, a transceiver module 68, a memory module 70 and an array processor module 72.
  • the pulse generator module 66 communicates with the operator console 20 over a serial data communications link 74.
  • the gradient amplifier system 80 comprises Gx, Gy and Gz gradient amplifiers 82 to 86 respectively.
  • the gradient amplifiers 82 to 86 receive input gradient pulse data from the system controller 60 and generate output gradient pulses that are conveyed to the MRI machine 120.
  • the RF coil control circuit 100 includes an output RF amplifier
  • the output RF amplifier 102 and input RF preamplifier 104 communicate with the transceiver module 68 of the system controller 60.
  • the T/R switch 106 is coupled to the MRI machine 120 and to the RF amplifier 102 and RF preamplifier 104.
  • the MRI machine 120 includes a cryostat 121 having a bore 122 to receive a patient P supported on table 123.
  • a magnet assembly 124 and RF coils 126 are disposed within the MRI machine 120.
  • the magnet assembly 124 includes a polarizing electromagnet 128 to generate a uniform static polarizing magnetic field B 0 and gradient coils 130 that are responsive to the output gradient signals generated by the gradient amplifiers 82 to 86.
  • Each gradient coil 130 is associated with a respective one of the gradient amplifiers.
  • the RF coils 126 are coupled to the T/R switch 106.
  • the MRI system 10 comprises a physiological acquisition controller 140, a scan room interface circuit 142 and a patient positioning system 144.
  • the physiological acquisition controller 140 is coupled to the pulse generator module 66 and to the MRI machine 120.
  • the scan room interface circuit 142 is coupled to the pulse generator module 66, the patient positioning system 144 and the MRI machine 120.
  • the patient positioning system 144 is also coupled to the MRI machine 120.
  • the physiological acquisition controller 140 receives signals from a number of different sensors connected to the patient P, such as ECG signals from electrodes attached to the patient, and conveys the signals to the pulse generator module 66.
  • the scan room interface circuit 142 receives input from various sensors associated with the condition of the patient and the magnet assembly 124 and conveys the signals to the pulse generator module 66.
  • the patient positioning system 144 receives commands from the scan room interface circuit 142 and in response moves the patient P within the MRI machine 120 to the desired location for the scan.
  • the general operation of the MRI system 10 will firstly be described for ease of understanding.
  • the patient P within the MRI machine 120 is subjected to a uniform static polarizing magnetic field B 0 produced by the polarizing electromagnet 128.
  • RF pulses are then generated by the RF coils 126 in a particular sequence and are used to scan target tissue of the patient.
  • MRI signals radiated by excited nuclei in the target tissue in the intervals between consecutive RF pulses are sensed by the RF coils 126.
  • the polarizing magnetic field is altered by the gradient coils 130 in response to received output gradient data thereby to position encode acquired MRI signals.
  • the sequence of RF pulses used to scan the patient P is generated by the RF coils 126 in response to pulse sequence data received from the pulse generator module 66 of the system controller 60 via the transceiver module 68 and RF coil control circuit 100.
  • the pulse sequence data determines the timing, strength and shape of the RF pulses in the pulse sequence as well as the MRI signal acquisition window.
  • the RF sequence data is generated by the pulse generator module 66 in response to scan commands received from the operator console 20 via the data communications link 74.
  • the RF coil control circuit 100 is conditioned to a transmit mode by the pulse generator module 66.
  • the T/R switch 106 couples the output RF amplifier 102 to the RF coils 126.
  • RF pulse data generated by the pulse generator module 66 is converted into an RF pulse via the transceiver module 68 and RF amplifier 102 and applied to the RF coils 126.
  • the pulse generator module 66 also generates gradient data in response to the scan commands received from the operator console 20 via the data communications line 74 and conveys the gradient data to the gradient amplifier system 80.
  • the gradient data determines the timing and shape of the output gradient pulses generated by the gradient amplifiers 82 to 86 that are applied to the gradient coils 130 during scanning.
  • the pulse generator module 66 conditions the RF coil control circuit 100 to a receive mode.
  • the T/R switch 106 couples the input RF preamplifier 104 to the RF coils 126.
  • the MRI signals radiated by excited nuclei in the target tissue are sensed by the RF coils 56 and conveyed to the transceiver module 68 via the T/R switch 106 and input RF preamplifier 104.
  • the amplified MRI signals are in turn demodulated, filtered and digitized by the transceiver module 68 and then transferred to the memory module 70.
  • FIG. 1 is a cutaway view of the MRI machine 120 and illustrates the spatial positioning of the polarizing electromagnet 128, RF coils 126, and gradient coils 130 within the MRI machine 120.
  • Contrast-enhanced MRI can generally be categorized as either positive or negative contrast. In positive contrast, image intensity increases at sites of MR contrast agent accumulation as a result of the dominating effect of a decreased longitudinal relaxation time Ti. In negative contrast, image intensity decreases at sites of MR contrast agent accumulation as a result of the dominating effect of a decreased transverse relaxation time T 2 (3). For illustrative purposes, the system and method will be described using activatable T 1 contrast agents.
  • the rate of molecular tumbling of a contrast agent in tissue is a factor in determining the relaxivity, n (4). Rapidly tumbling molecules exhibit lower relaxivities (typically ⁇ 10 s "1 mM ⁇ 1 ) that decline gradually with increasing magnetic field strengths above 0.5 T. Activatable contrast agents are designed to bind more specifically and strongly to certain proteins or classes of proteins or other macromolecular or cellular entities. Upon binding, the resulting decreased tumbling rate has been shown to produce a dramatic increase in relaxivity r ⁇ at low magnetic field strengths (e.g. less than about 0.5 T), with relatively little enhanced relaxivity at higher field strengths (e.g. above 3 T).
  • Vasovist or MS-325 (Bayer Healthcare Pharmaceuticals,
  • Gadofosveset trisodium is one particular example of a gadolinium chelate of similar size to conventional Gd-DTPA.
  • this molecule shows strong non-covalent binding to human serum albumin (HAS) (5,6).
  • HAS human serum albumin
  • the bound form of this contrast agent demonstrates an increase of relaxivity by approximately an order of magnitude at 30 Mhz, and approximately four-fold at 60 MHz.
  • the relaxivity curves of Vasovist in the presence and absence of human serum albumin and rabbit serum albumin are shown in Figure 3 (7).
  • the contrast agent bis- ⁇ -HT-DTPA(Gd) has been developed as a "sensor" of the enzyme myeloperoxidase (8).
  • this contrast agent converts from a monomeric form with minimal protein binding characteristics and relaxivity similar to that of Gd-DTPA, to an oligomeric form with stronger protein binding affinity, leading to enhanced relaxivity.
  • Another gadolinium-based contrast agent EP-2104R (Epix Pharmaceuticals), is currently in clinical trials (9). This contrast agent will selectively bind to fibrin, a significant component of blood clots (thrombi). Upon binding, contrast agent EP-2104R demonstrates a 2.3-times increase in relaxivity at a magnetic field strength equal to 1.5 T.
  • gadolinium-based contrast agents represent the promise of activatable MRI contrast agents, but also illustrate a limitation of this class of agents. That is, the activation-induced relaxivity enhancement may be relatively modest, especially at clinical magnetic field strengths of 1.5 T or 3 T. As a result, it may be difficult to separate intensity enhancement due to the presence of the activated contrast agent from intensity enhancement due to the presence of larger amounts of the non-activated contrast agent.
  • the relaxivity enhancement ratio that is the ratio of the activated relaxivity to the inactivated relaxivity.
  • the relaxivities in the presence and absence of albumin are 19 s "1 mM '1 and 5.2 s "1 mM '1 respectively, resulting in a relaxivity enhancement ratio of 3.7. From Figure 3 it can be seen that the Vasovist relaxivity enhancement ratio peaks in the vicinity of a magnetic filed strength equal to 0.5 T, and falls quickly for magnetic field strengths above that value.
  • the subject system and method can distinguish between signal intensities produced by tissues containing activated contrast agent from other sources of signal intensity, using an approach termed delta relaxation enhanced MR (DREMR) (10).
  • DREMR is an MRI method that produces image contrast related to the dependence of relaxation rate upon the strength of the applied polarizing magnetic field as a means to differentiate the activation (binding) state of a targeted contrast agent, where an activated contrast agent demonstrates magnetic field dependence while an inactivated contrast agent does not.
  • DREMR finds its roots in field-cycling relaxometry imaging methods used by Carlson et al. (11) as a means to differentiate biological tissues.
  • the relaxivity slope enhancement ratio (ratio of activated ri to inactivated ri) is 90 at a magnetic field strength equal to 1.5 T. This represents a 25-fold increase over the absolute relaxivity enhancement ratio of 3.7 mentioned above.
  • the high specificity of DREMR enhancement is not specific to Vasovist but applies to any T 1 contrast agent that undergoes binding to large molecules (15).
  • Transforming R 1 ' into image contrast requires the ability to dynamically vary the strength of the main polarizing magnetic field in an MRI system. Access to such platforms is limited to a handful of sites worldwide (16- 18). A more accessible and convenient approach described herein, involves providing conventional MRI machines with the ability to generate an auxiliary magnetic field ( ⁇ B) to enable variable polarizing magnetic field operation.
  • ⁇ B auxiliary magnetic field
  • One such approach involves providing the MRI machine with an electromagnetic coil insert ( ⁇ B insert) to enable variable polarizing magnetic field operation.
  • ⁇ B insert electromagnetic coil insert
  • Another approach involves reprogramming a gradient coil within the MRI machine to enable variable polarizing magnetic field operation.
  • Still another approach involves providing the MRI machine with a modified gradient coil to enable variable polarizing magnetic field operation.
  • the ⁇ B auxiliary magnetic field is applied during a relaxation portion of an MRI pulse sequence.
  • the ⁇ B magnetic field is applied during the longitudinal relaxation portions (T 1 ) of the MRI pulse sequence where extremely high stability and homogeneity are not necessary.
  • the main polarizing magnetic field is not altered by the ⁇ B auxiliary magnetic field during actual signal sensing or any RF pulse application. This means that the normal RF transmit/receive chain can be used without modification.
  • the theory and an experimental demonstration of DREMR are presented, using a small-bore actively-shielded field-cycling electromagnet within an otherwise conventional 1.5 T clinical MRI machine.
  • Various methods can be employed to generate DREMR contrast.
  • the simplest method involves the weighted subtraction of two Ti weighted images, each image acquired with a slightly different MRI pulse sequence.
  • These MRI pulse sequences referred to as the T 1+ and T 1 . sequences, both resemble Ti weighted sequences; however, in the T 1+ sequence a magnetic field increasing ⁇ B auxiliary magnetic field pulse is applied during longitudinal relaxation, while in the T 1 . sequence a magnetic field decreasing ⁇ B auxiliary magnetic field pulse is used.
  • the Ti + and T 1 . sequences are shown.
  • Each pulse sequence contains a relaxation portion where the static polarizing magnetic field strength (B 0 ) is either increased or decreased by an amount ⁇ B, as well as a self-contained signal sensing or acquisition portion, which may be a conventional imaging sequence such as, spin-echo, fast spin-echo, etc.
  • a spin-echo signal acquisition portion is shown.
  • each relaxation portion begins with a saturation RF pulse to eliminate any preexisting longitudinal magnetization; however, other initialization states could be used in a similar analysis.
  • the effect of finite ramping times for the ⁇ B auxiliary magnetic field pulse will be ignored.
  • the steady state longitudinal magnetization (M 0 ) is proportional to the amplitude of the applied magnetic field.
  • R 1 . will indicate the longitudinal relaxation rate of the sample at the reduced polarizing magnetic field strength of B 0 - ⁇ ⁇ , while R 1+ indicates the R 1 at an increased polarizing magnetic field strength. Note that R 1 . may be greater than R 1+ .
  • the longitudinal voxel magnetization following negative and positive ⁇ B auxiliary magnetic fields are expressed by Equations [1] and [2] below:
  • Image voxel intensity is determined by the combined actions of the signal acquisition module, MRI machine signal detection hardware, and console software. For simplicity it will be assumed that the final image intensity is a product of the actual voxel magnetization (M 2 ), and a single positionally dependent term, k, that incorporates proton density, RF coil homogeneity, transverse relaxation time, and any other scaling factors.
  • Forming the DREMR image requires taking the weighted difference of the /. and /+ images. Due to the different equilibrium magnetization introduced by the perturbation magnetic field, the image magnitudes /. and / + must be normalized prior to subtraction:
  • Equation 4 There are two non-linear terms in Equation 4, namely the hyperbolic sine and exponential decay functions.
  • the hyperbolic sine term though non-linear, is responsible for the distinctive contrast produced by this method. It indicates that difference in intensity between voxels in the final DREMR image will be related to the Ri values of those voxels.
  • the exponential decay function results in image shading when the longitudinal relaxation time t A is set too long and the voxel magnetizations of the /. and /+ images begin to saturate. This is comparable to using a T R much longer than Ti when taking a T 1 weighted image.
  • Equation 5a shows that with the appropriate choice of fo image intensity becomes linear with ARi.
  • Equation 5b expresses the result more explicitly with ARi replaced by the product of Ri and ⁇ B; that is, the slope of Ri multiplied by the strength of the magnetic field shift: I S ⁇ h * 2k - M 0 -t A - AR ⁇ [5a] / Sub » 2k - M 0 - t li - AB - R, [5b]
  • DREMR This is the simplest implementation of DREMR. With this implementation, it is possible to produce image intensities that depend on the change in R 1 rather than in R 1 itself. Activatable contrast agents of the types described herein all produce major changes in R 1 ' upon activation, even if the enhancement in Ri is much smaller. This mathematical basis for one implementation of DREMR illustrates its potential application to the specific imaging of activatable MRI contrast agent probes. [0082] DREMR results in a reduction of signal to noise ratio (SNR). Because of the restrictions placed previously, that is ⁇ R 1 ⁇ 0.2, the SNR of the constituent images, /.
  • SNR signal to noise ratio
  • Equation 6 again involves an approximation; it is assumed the magnetic field shifts about Bo are small enough such that the uncertainties of the /. and /+ images are identical. When the magnetic field shifts are larger, the SNR equation must take into account the different uncertainties in each image. [0084] For an R/- ⁇ B (AR 1 ) of 1 s "1 and an R 1 of 10 s ⁇ ⁇ the SNR of the
  • DREMR image drops to 14% of the SNR of the source image. Beyond simply gauging the loss in SNR, Equation 6 illustrates that the maximum SNR would be produced by contrast agents that demonstrate a sharp change in r-i (large r/) for a small value of o . Evaluation of the ril r ? of a molecular probe may provide a basis for evaluating which molecular probes would benefit from DREMR contrast.
  • DREMR contrast is now illustrated with reference to the following examples that provide experimental and computer simulated results.
  • Example 1 A double subtraction method for example could utilize several inversion pulses as well as several ⁇ S auxiliary magnetic field pulses to achieve DREMR contrast without subtraction.
  • Example 1 A double subtraction method for example could utilize several inversion pulses as well as several ⁇ S auxiliary magnetic field pulses to achieve DREMR contrast without subtraction.
  • Vasovist (MS-325) was imaged in the presence and absence of rabbit serum albumin (RSA). As shown in Figure 3, Vasovist preferentially binds to albumin, producing moderate enhancement in the inactivated state and higher enhancement in the activated state.
  • RSA rabbit serum albumin
  • agent/protein pair was based by the availability of the contrast agent and its well-documented relaxivity mechanisms, rather than any specific clinical or research interest in albumin.
  • An MRI phantom (see Figure 5a) was constructed that held two columns of six rows of glass tubes; each tube 3 cm in length with a 0.4 ml_ capacity.
  • the sample tubes in the left column were filled with 0.01 M phosphate buffered saline (PBS) (NaCI 0.138M, KCI 0.0027M, pH 7.4 at 25 0 C).
  • PBS phosphate buffered saline
  • the right column of sample tubes held a solute of rabbit serum albumin (Sigma-Aldrich, batch 104K7560, agarose gel electrophoresis) in PBS.
  • the albumin purchased as a lyophilized powder, was dissolved in PBS, at a 4.5% weight to volume ratio resulting in ⁇ 0.67mM concentration.
  • Vasovist (0.25 mmol/mL) was added in equal concentration to both columns to achieve sample concentrations of 0, 10, 20, 40, 80 and 160 ⁇ M as a function of descending rows.
  • Imaging was performed on a Sigma LX 1.5 T clinical MRI machine
  • the ⁇ B insert designed to generate ⁇ ⁇ B auxiliary magnetic field pulses, had an efficiency of 0.7 mT/A, weighed approximately 150 kg and was designed to facilitate the imaging of animals as large as rabbits.
  • the ⁇ B insert was driven by a pair of Techron 8607 gradient amplifiers arranged in a master/slave series configuration enabling a maximum bipolar output of 100A.
  • Input waveforms to the gradient amplifiers were generated by National Instruments data acquisition hardware and controlled via software written in LabView (National Instruments, version 8.2). Waveform synchronization between the data acquisition device and the MRI console was achieved by means of the 'scope trigger' output of the console electronics.
  • the following spin-echo pulse sequence parameters were used for all images that were combined to produce the final DREMR image: 150 ms pulse repetition time, 10 ms echo time, 31 kHz bandwidth, 8 cm field of view and 10 mm slice thickness. The scan time was 24s for each image. For each row of /c-space, 70 mT AB auxiliary magnetic field pulses were applied for 100-ms intervals. The ⁇ B auxiliary magnetic field pulses were timed to end 10 ms prior to image acquisition to give both the polarizing magnetic field and amplifiers time to stabilize.
  • T 1+ images the polarizing magnetic field was increased by 70 mT during the relaxation portion of the MRI pulse sequence. Likewise for T 1 . images the polarizing magnetic field was decreased by the same amount.
  • Ten pairs of T 1+ and T 1 . weighted images were acquired for the samples held at 21 0 C. Acquisitions of T 1+ and T 1 . enhanced images were interleaved to minimize heating of the amplifiers. The positively enhanced images were then averaged into a single dataset, as were the negatively enhanced images. The resulting two datasets were normalized and the absolute difference taken to produce contrast related to the magnetic field dependence of R 1 . Unlike in the theoretic treatment a saturation pulse was not applied prior to the ⁇ B auxiliary magnetic field pulse. Standard Ti weighted spin-echo images using the same MRI pulse sequence parameters were acquired for comparison.
  • Figure 5b shows the standard T 1 weighted spin-echo image of the samples.
  • the intensity of both columns increased from top to bottom with concentration of Vasovist.
  • the measured average intensity within each sample is plotted in Figure 6a.
  • the error bar on each data point indicates the standard deviation of voxel intensity throughout the corresponding sample.
  • Both sets of samples, albumin solution and PBS demonstrated significant dependence on Vasovist concentration. Because the range of intensities of the albumin samples (A) were not clearly separated from those of the PBS samples (•) but in fact were appreciably overlapped, it is clear that without prior knowledge of Vasovist concentrations, it would not be possible to differentiate the albumin-containing sample from PBS-only samples based on T 1 weighted image intensity alone.
  • Figure 5c illustrates the absolute difference of the ⁇ ⁇ S auxiliary magnetic field datasets.
  • the figure shows the entire dynamic range without thresholding.
  • the average intensity from each of the samples is plotted in Figure 6b.
  • the standard deviation of voxel intensities within each sample is again expressed as an error bar.
  • the image intensity of albumin samples continued to demonstrate dependence on Vasovist concentration, the PBS samples were significantly suppressed.
  • the intensities of all PBS samples were suppressed well below the intensity of the weakest albumin-loaded sample, which had only a 10 ⁇ M Vasovist concentration.
  • a substantially increased specificity to albumin was obtained through DREMR imaging.
  • Example 2 [0095] The embodiments described in this Example allow for generation of an auxiliary magnetic field, without the need for the auxiliary electromagnetic insert described in Example 1.
  • the embodiments described in this Example involve either an unmodified MRI system or an MRI system comprising a modified gradient coil system.
  • the modified gradient system may be used to produce both linearly varying and uniform polarizing magnetic fields across the imaging region.
  • Figure 7 one embodiment is shown in which a standard spin- echo pulse sequence has been modified to include gradient-induced magnetic field pulses during the relaxation portion of the MRI pulse sequence.
  • the choice of spin-echo pulse sequence is consistent with Figure 4 which used a spin-echo pulse sequence to generally illustrate the timing of ⁇ B auxiliary magnetic field generation.
  • Figure 7 shows that all three gradient coils (Gs, Gp, and Gf, also known as Gz, Gx and Gy, respectively) are applied at the same time to generate ⁇ B auxiliary magnetic field pulses throughout time T ⁇ .
  • T ⁇ occurs within the T 1 relaxation portion of the pulse sequence.
  • T ⁇ in Figure 7 and t ⁇ in Figure 4 are used interchangeably to designate the ⁇ B auxiliary magnetic field pulse duration).
  • Figure 9 shows a schematic of a typical unmodified longitudinal gradient coil connected to a set of amplifiers.
  • the typical longitudinal gradient coil can be thought of as two distinct coils electrically wired in series. By electrically separating the two halves of the gradient coil and attaching each half to a separate amplifier, each half of the gradient can be independently controlled.
  • the modified gradient coil behaves in the typical gradient coil fashion and a linearly varying magnetic field is produced for MR image formation (plotted as 'Gradient Mode' in Figure 12).
  • the amplifiers cause current with opposite polarities to flow (Figure 11) the modified gradient coil behaves as a ⁇ B coil, in that it generates a substantially uniform auxiliary magnetic field across the imaging region (plotted as ' ⁇ B mode' in Figure 12), ideally producing a magnetic field shift that is invariant with position.
  • a modified gradient coil will produce a constant auxiliary magnetic ( ⁇ B) field during the relaxation portion of the MRI pulse sequence ( Figure 7) and a varying magnetic (gradient) field during the imaging portion of the MRI pulse sequence.
  • ⁇ B auxiliary magnetic
  • gradient gradient
  • Figures 13 and 14 show the wire pattern for one particular embodiment of a modified gradient coil. Current direction is indicated by the color coding of the wire; black indicates that current flow is parallel to the x-axis and grey indicates anti-parallel current flow.
  • the gradient coil behaves like a traditional gradient coil.
  • FIG 9 the current direction is reversed in the top half of the coil and the modified gradient coil behaves like a ⁇ coil.
  • similar approaches may be used to modify the transverse (x and y) gradient coils to allow dual operation as either a conventional gradient coil or a AB coil.
  • Current direction is indicated by the color coding of the wire; black lines indicate current flow parallel to the y-axis and grey lines indicates current flow anti-parallel to the y- axis.
  • Figure 15 shows the wire pattern of a particular embodiment of a transverse gradient coil when used in gradient mode. When the polarity of current is changed in half of the gradient coil only ( Figure 16), the coil acts as a ⁇ coil and produces a uniform magnetic field profile.
  • Embodiments that provide conventional gradient coils with the target in the iso-center, conventional gradient coils with the target offset from the iso-center, and a modified longitudinal gradient coil with the target in the iso- center were analyzed using computer simulations. As a comparator, a standard Ti weighted image was also produced.
  • the target being imaged is a tumour (represented by a circle) that is surrounded with interstitial fluid (each quadrant representing a distinct concentration of Vasovist).
  • the tumor contains the protein albumin, which is not found in the surrounding fluid.
  • Albumin binds to the contrast agent Vasovist.
  • Vasovist is used to enhance the tumor, but due to leaky vasculature also enhances the interstitial fluid.
  • the concentration of Vasovist is 20 ⁇ M, while outside the tumor the concentration of Vasovist varies from 20 to 160 ⁇ M as shown in Figure 17.
  • tumour and interstitial fluid Vasovist and albumin concentrations are identical for each of Figures 17, 18, 20 and 22.
  • Figure 17 shows that standard Ti weighting is insufficient to enhance the tumour over the interstitial fluid.
  • DREMR can be used to create image contrast that preferentially enhances locations where the protein albumin has bound the Vasovist contrast agent (e.g. inside the tumour).
  • DREMR uses an auxiliary magnetic field shift to produce the unique contrasts.
  • the auxiliary magnetic field, ⁇ B is achieved by the longitudinal gradient coil of the MRI system.
  • Figure 18 shows a simulated DREMR image of the tumour.
  • the DREMR contrast has been created by applying a linearly varying magnetic field across the image.
  • the ⁇ B auxiliary magnetic field increases from -1 OmT on the left to 10mT on the right to produce a first T 1 weighted image.
  • the ⁇ B auxiliary magnetic field is then reversed to produce a second Ti weighted image. Subtraction of the first and second Ti weighted images produces the DREMR image.
  • Figure 19 shows the setup for Figure 18.
  • FIG. 18 shows that in the middle of the tumour (circle) there is no contrast between the tumour and the background, as the middle of the tumour coincides with the iso-center.
  • Figure 20 shows a simulated DREMR image where the sample has been shifted off-axis, but is otherwise the same setup as used for Figure 18.
  • the ⁇ B auxiliary magnetic field increases from 2OmT on the left to 4OmT on the right to produce a first Ti weighted image.
  • Figure 20 shows a significant improvement over Figures 17 and 18; however some shading still exists across the tumour. Further improvements in image quality can be achieved as a function of averaging and/or offset positioning from multiple axes.
  • Figure 21 shows the setup for Figure 20. The tumour has been placed off-axis where the ⁇ B auxiliary magnetic field generated by the gradient coil during the relaxation portion of the pulse sequence is consistently positive (shown), or consistently negative when the ⁇ B auxiliary magnetic field is reversed (not shown).
  • Figure 22 shows a simulated DREMR image where the sample is at iso-center and a modified gradient coil as shown in Figures 10 to 14 has been used to generate a substantially uniform ⁇ B auxiliary magnetic field at all points across the imaging region.
  • the ⁇ B auxiliary magnetic field of 4OmT is used to produce a first Ti weighted image.
  • the ⁇ B auxiliary magnetic field is then reversed at -4OmT to produce a second Ti weighted image.
  • Subtraction of the first and second T 1 weighted images produces the DREMR image.
  • the image shown in Figure 22 benefits from a lack of shading across the tumour, thereby increasing contrast over the background interstitial fluid. Furthermore, this image quality can be produced independent of the positioning of the target sample, including positioning at the iso-center.
  • Figure 23 shows the setup for Figure 22.
  • the tumour is placed at the iso-center similar to the setup for Figure 18, but because the modified gradient coil generates a substantially uniform ⁇ B auxiliary magnetic field across the target sample an improved image is obtained in Figure 22 compared to Figures 17, 18 and 20.
  • the software application used to drive the electromagnetic ⁇ B insert, the gradient coil, or the modified gradient coil may run as a stand-alone application or may be incorporated into other available applications to provide enhanced functionality to those applications.
  • the software application may comprise program modules including routines, programs, object components, data structures etc. and may be embodied as computer readable program code stored on a computer readable medium.
  • the computer readable medium is any data storage device that can store data, which can thereafter be read by a computer system.
  • Examples of computer readable media include for example read-only memory, random-access memory, CD-ROMs, magnetic tape and optical data storage devices.
  • the computer readable program code can also be distributed over a network including coupled computer systems so that the computer readable program code is stored and executed in a distributed fashion.
  • the method and system take advantage of the change in longitudinal relaxivity vs. field strength, i.e. the relaxivity slope, to generate selective image contrast occurring when a contrast agent binds to a given target molecule. In other embodiments, variations other than the slope may be examined.
  • the system and method have been described in respect of embodiments relating to Ti relaxation times and Ti contrast agents.
  • the system and method may be adapted to produce image contrast related to the magnetic field dependence of T 2 contrast agents.
  • the system and method described herein is readily applicable to any type of MRI machine, for example bore or gap-type MRI machines.
  • the polarizing magnetic field B 0 generated by the MRI machine may be of any desired strength, but will typically be greater than 0.2 T.
  • the system and method have been described with respect to embodiments where an auxiliary magnetic field is provided by either an insert or a gradient coil. It will be recognized that various MRI pulse sequences may be combined with gradient pulses during the relaxation portion of the pulse sequence to produce image contrast.
  • any number of gradient coils may be used to generate the ⁇ B magnetic field during the relaxation portion of the pulse sequence, for example one gradient coil may be used alone or multiple gradient coils may be used in combination.
  • Any conventional gradient coil can be reprogrammed or modified in accordance with the system and method described herein, including for example flat or planar gradient coils.
  • the target When offsetting a target from the iso-center, the target may be offset along one or more of the x, y and z axis of a Cartesian coordinate system.
  • the above-described embodiments are intended to be examples and alterations and modifications may be effected thereto, by those of skill in the art, without departing from the scope of the invention which is defined by the claims appended hereto.

Abstract

A method for contrast agent enhanced magnetic resonance imaging (MRI) of a target sample, comprising generating a magnetic field shift in a polarizing magnetic field during a relaxation portion of an MRI pulse sequence and thereafter acquiring an MR image.

Description

SYSTEM AND METHOD FOR MAGNETIC RESONANCE IMAGING
Cross-Reference To Related Applications
[0001] This application claims the benefit of U.S. Provisional Application No. 61/108,734 to Alford et al. filed on October 27, 2008 entitled "System and Method for Magnetic Resonance Imaging", the content of which is incorporated herein by reference.
Field of the Invention
[0002] This specification relates generally to magnetic resonance imaging and more particularly, to a system and method for producing image contrast in magnetic resonance imaging.
Background of the Invention
[0003] Molecular imaging is the in vivo study and measurement of biological processes at the molecular level (1). Nuclear Magnetic Resonance (NMR) Imaging, or Magnetic Resonance Imaging (MRI) as it is commonly known, is a non-invasive imaging modality that can produce high resolution, high contrast images of the interior of a subject. MRI involves the interrogation of the nuclear magnetic moments of a sample placed in a strong magnetic field with radio frequency (RF) magnetic fields. During MRI the subject, typically a human patient, is placed into the bore of an MRI machine and is subjected to a uniform magnetic field B0 produced by a polarizing magnet housed within the MRI machine. Radio frequency (RF) pulses, generated by RF coils housed within the MRI machine in accordance with a particular localization method, are typically used to scan target tissue of the patient. MRI signals are radiated by excited nuclei in the target tissue in the intervals between consecutive RF pulses and are sensed by the RF coils. During MRI signal sensing, gradient magnetic fields are switched rapidly to alter the uniform magnetic field at localized areas thereby allowing spatial localization of MRI signals radiated by selected slices of the target tissue. The sensed MRI signals are in turn digitized and processed to reconstruct images of the target tissue slices using one of many known techniques.
[0004] When a target substance, such as human tissue, is subjected to the static polarizing magnetic field B0, the individual magnetic moments of the spins in the tissue attempt to align with the static polarizing magnetic field B0, but precess about the static polarizing magnetic field B0 in random order at their characteristic Larmor frequency. The net magnetization vector lies along the direction of the static polarizing magnetic field B0 and is referred to as the equilibrium magnetization Mo. In this configuration, the Z component of the magnetization or longitudinal magnetization Mz is equal to the equilibrium magnetization Mo. If the target tissue is subjected to an excitation magnetic field Bi, which is in the x-y plane and which is near the Larmor frequency, the longitudinal magnetization Mz may be rotated, or "tipped" into the x-y plane to produce a net transverse magnetic moment Mχγ_ When the excitation magnetic field Bi is terminated, relaxation of the excited spins occurs, with a signal being emitted that effects the magnitude of radiated MRI signals. The emitted signal is received and processed to form an image.
[0005] In particular, when the excitation magnetic field Bi is terminated, the longitudinal magnetization Mz relaxes back to its equilibrium. The time constant that describes how the longitudinal magnetization Mz returns to its equilibrium value is commonly referred to as the spin lattice relaxation time T1. The spin lattice relaxation time Ti characterizes the time required to reduce the difference between the longitudinal magnetization Mz and its equilibrium longitudinal magnetization value M0 to zero. [0006] The net transverse magnetic moment MXγ also relaxes back to its equilibrium when the excitation magnetic field Bi is terminated. The time constant that describes how the transverse magnetic moment MXY returns to its equilibrium value is commonly referred to as transverse relaxation time or spin- spin relaxation time T2. The transverse relaxation time T2 characterizes the time required to reduce the transverse magnetic moment MXγ to zero. Both the spin lattice relaxation time T1 and the transverse relaxation time T2 are tissue specific and vary with concentration of different chemical substances in the tissue as well as with different microstructural features of the tissue. Variations of the spin lattice relaxation time T1 and/or the transverse relaxation time T2 from normal can also be indicative of disease or injury.
[0007] Like many diagnostic imaging modalities, MRI can be used to differentiate tissue types, e.g. muscles from tendons, white matter from gray matter, healthy tissue from pathologic tissue, etc. There exist many different MRI techniques, the utility of each depending on the particular tissues under examination. Some techniques examine the rate of tissue magnetization, while others measure the amount of bound water or the velocity of blood flow. Often, several MRI techniques are used together to improve tissue identification. In general, the greater the number of identification methods available the better chance of identifying a certain tissue type or pathology. [0008] In some instances, contrast agents or contrast materials may be used to emphasize certain anatomical regions. For example, a Gadolinium chelate injected into a blood vessel will produce enhancement of the vascular system, or the presence and distribution of leaky blood vessels. Iron-loaded stem cells, injected into the body and detected by MRI, will allow stem cell migration and implantation in vivo to be tracked. [0009] Contrast agents can enhance imaging of target sites or tissues through the complementary processes of accumulation and activation. Accumulation occurs when the local concentration of the contrast agent is increased through metabolic uptake or molecular adhesion leading to localized image enhancement. A growing number of contrast agents are also activatable, their behavior mediated by interaction with a target molecule, such as a specific protein or macromolecule. Contrast agents demonstrating activation are interchangeably called "sensing", "smart", or "activatable" contrast agents. [0010] Activatable contrast agents are used in MRI studies to improve the specificity of the contrast agent (2). Ideally activatable contrast agents produce no image enhancement in the inactivated state; however, to date, these contrast agents combined with conventional MRI have shown image intensity enhancement in both inactivated and activated states, with relatively modest signal intensity ratios between these two states. [0011] Accordingly, there is a continuing need for improvements in MRI.
It is therefore an object of an aspect to provide a novel system and method for producing image contrast in magnetic resonance imaging.
Summary of the Invention [0012] Accordingly, in one aspect there is provided a method for contrast agent enhanced magnetic resonance imaging (MRI) of a target sample, comprising generating a magnetic field shift in a polarizing magnetic field during a relaxation portion of an MRI pulse sequence and thereafter acquiring an MR image. [0013] In another aspect, there is provided a method of magnetic resonance imaging comprising subjecting a sample to polarizing magnetic fields of different strengths and acquiring a scan associated with each polarizing magnetic field; and processing the scans to generate selective image contrast of said sample based on the variation of at least one MR property of the sample in response to the different polarizing magnetic field strengths.
[0014] In yet another aspect, there is provided a magnetic resonance imaging method comprising performing multiple scans of a subject and generating an image for each scan, each scan being conducted utilizing a different polarizing magnetic field; and processing the images to yield an enhanced contrast image, wherein said performing comprises: shifting the polarizing magnetic field of an MRI machine in one direction during a relaxation portion of a first pulse sequence and thereafter acquiring an image; and shifting the polarizing magnetic field of the MRI machine in an opposite direction during a relaxation portion of a second pulse sequence and thereafter acquiring an image.
[0015] In still another aspect, there is provided an MRI machine comprising a housing having a bore in which a subject to be imaged is placed; a polarizing electromagnet accommodated by said housing and generating a generally uniform polarizing magnetic field within said bore; pulse generating coils to generate pulses in a sequence to scan the subject; and gradient coils to encode acquired MRI signals, wherein said gradient coils are futher configured to genate a shift in the polarizing magnetic field during a relaxation portion of the sequence.
Brief Description of the Drawings
[0016] Embodiments will now be described, by way of example only, with reference to the accompanying drawings in which:
[0017] Figure 1 is a schematic block diagram of an MRI system;
[0018] Figure 2 is a cutaway view of an MRI machine forming part of the
MRI system of Figure 1 ;
[0019] Figure 3 is a graph of relaxivity as a function of field strength for the activatable contrast agent Vasovist alone (+) or in the presence of human
(o) or rabbit (Δ) serum albumin;
[0020] Figure 4 is a schematic of (a) the Ti+ sequence and (b) the "resequence of spin-echo pulse sequences where an auxiliary-magnet-induced ΔB magnetic field pulse of duration tΔ has been used to modify the strength of the static Bo field during a Ti relaxation portion of the sequences;
[0021] Figure 5 shows (a) an experimental sample and its MRI resulting in (b) a conventional Ti weighted image and (c) a Ti weighted image using the system and method described herein;
[0022] Figure 6 graphs the sample intensities found in the images shown in Figure 5 (b) and (c);
[0023] Figure 7 is a schematic of a spin-echo pulse sequence where a gradient coil-induced ΔB magnetic field pulse of duration tΔ has been used to modify the strength of the static B0 field during a T1 relaxation portion of the sequence; [0024] Figure 8 shows placement of a target sample offset from the iso- center;
[0025] Figure 9 shows the current path of a conventional longitudinal (i.e., z-axis) gradient coil;
[0026] Figure 10 shows the current path of the gradient coil shown in Figure 9 modified in accordance with the system and method described herein, when the modified gradient coil is used to generate a varying magnetic field across an imaging region;
[0027] Figure 11 shows the current path of the modified gradient coil shown in Figure 10, when the modified gradient coil is used to produce a substantially uniform magnetic field across the imaging region;
[0028] Figure 12 is a graph showing the two magnetic fields that can be generated by the modified gradient coil shown in Figures 10 and 11 plotted as a function of the spatial position within the imaging region with 0 indicating the iso- center; [0029] Figure 13 shows the wire pattern and current flow of the modified gradient coil shown in Figure 10;
[0030] Figure 14 shows the wire pattern and current flow of the modified gradient coil shown in Figure 11 ;
[0031] Figure 15 shows the wire pattern and current flow of a transverse gradient coil, modified in accordance with the system and method described herein, when the modified gradient coil is used to generate a varying magnetic field across an imaging region;
[0032] Figure 16 shows the wire pattern and current flow of the modified gradient coil shown in Figure 15, when the modified gradient coil is used to produce a substantially uniform magnetic field across the imaging region;
[0033] Figure 17 shows a computer simulation of a conventional T1 weighted image of a tumour over its surrounding interstitial fluid at various concentrations of the activatable contrast agent, Vasovist;
[0034] Figure 18 shows a computer simulation of a T1 weighted image of the tumour and surrounding interstitial fluid as shown in Figure 17 obtained with the tumour positioned at the iso-center and using a conventional MRI machine with the z-gradient coil programmed to generate a ΔB magnetic field that is linearly varying across the imaging region;
[0035] Figure 19 shows the ΔB magnetic field and tumour position used to obtain the image shown in Figure 18;
[0036] Figure 20 shows a computer simulation of a T1 weighted image of the tumour and surrounding interstitial fluid as shown in Figures 17 and 18 obtained with the tumour positioned offset from the iso-center and using a conventional MRI machine with the z-gradient coil programmed to generate a ΔB magnetic field that is linearly varying across the imaging region; [0037] Figure 21 shows the ΔB magnetic field and tumour position used to obtain the image shown in Figure 20;
[0038] Figure 22 shows a computer simulation of a T1 weighted image of the tumour and surrounding interstitial fluid as shown in Figures 17, 18 and 19 obtained with the tumour positioned located at the iso-center and using an MRI machine with a modified z-gradient coil programmed to generate a ΔB magnetic field that is substantially uniform across the imaging region; and
[0039] Figure 23 shows the ΔB magnetic field and tumour position used to obtain the image shown in Figure 22.
Detailed Description
[0040] Embodiments described in the present specification relate to a method and system for magnetic resonance imaging of samples which make use of a dynamically controlled MRI polarizing magnetic field and a contrast agent or endogenous substance that demonstrates a magnetic field-dependent variation in one or more MRI properties. The system and method described herein provide increased specificity in MRI by utilizing an auxiliary magnetic field to modify the strength of the main polarizing magnetic field as a function of time during a relaxation portion of an MRI pulse sequence. [0041] In one embodiment, an auxiliary magnetic field ΔB is applied during a relaxation portion of an MRI pulse sequence. More specifically, during the relaxation portion of the MRI pulse sequence the static magnetic field strength B0 generated by the polarizing magnet of an MRI machine is either increased or decreased by an amount ΔB. The auxiliary magnetic field may be applied during part, substantially all, or all of the relaxation portion of the MRI pulse sequence. [0042] Various examples of generating and applying the magnetic field ΔB are described herein. In one embodiment, an electromagnetic coil insert (ΔB insert) is incorporated into a conventional MRI machine, to generate a substantially uniform magnetic field, across an imaging region, during a relaxation portion of an MRI pulse sequence. In another embodiment, a gradient coil in a conventional MRI machine is programmed to generate a varying magnetic field, across an imaging region, during a relaxation portion of the MRI pulse sequence, with the target sample being placed offset from the iso-center of the MRI machine. In still another embodiment, a gradient coil is modified to generate a substantially uniform magnetic field, across an imaging region, during a relaxation portion of the MRI pulse sequence. [0043] "Iso-center" refers to a location within an MRI machine where a varying magnetic field generated by a gradient coil is zero. Thus, in embodiments where a gradient coil induced linearly varying magnetic field is produced during a relaxation portion of the MRI pulse sequence, offsetting the target sample from the iso-center allows for the gradient coil induced magnetic field to be non-zero across the target sample. The iso-center typically coincides with the spatial center of a magnet assembly in an MRI machine.
[0044] "Relaxation" refers to a return of excited spins to their equilibrium distribution in which there is no transverse magnetization and/or the longitudinal magnetization is at its maximum value and oriented in the direction of the main static magnetic field B0 generated by the MRI machine. After excitation the transverse magnetization decays toward zero with a characteristic time constant T2, and the longitudinal magnetization returns toward equilibrium with a characteristic time constant Ti. The method and system take advantage of the change in longitudinal relaxivity vs. magnetic field strength, i.e. the relaxivity slope, to produce selective image contrast when a contrast agent binds to a given target molecule.
[0045] Turning now to Figure 1 , an MRI system is shown and is generally identified by reference numeral 10. The MRI system 10 comprises an operator console 20, a computer system 40, a system controller 60, a gradient amplifier system 80, an RF coil control circuit 100 and an MRI machine 120. The operator console 20 allows an operator to control the MRI system 10 including the production and display of images. The computer system 40 is responsive to commands generated by the operator console 120 and generates images for display. The system controller 60 communicates with the operator console 20, the computer system 40, the gradient amplifier system 80 and the RF coil control circuit 100 and orchestrates the acquisition of images in response to commands generated by the operator console 20. The MRI machine 120 communicates with the gradient amplifier system 80 and the RF coil control circuit 100.
[0046] The operator console 20 comprises an input device 22, a control panel 24 coupled to the input device 22, and a display 26. The input device 22 can comprise a mouse, joystick, keyboard, trackball, touch screen, light wand, voice control, or similar such device, and may be used for interactive geometry prescription. The operator console 20 communicates with the computer system 40 over a data communications link 28 thereby to enable an operator to control the production and presentation of images on the display 26. [0047] The computer system 40 comprises a number of modules, which communicate with each other through a backplane 42. As can be seen, the modules of computer system 40 comprise an image processor module 44, a CPU module 46, and a memory buffer 48, known in the art as a frame buffer for storing image data arrays. The computer system 40 is linked to a disk storage 50 and a tape drive 52 for storage of image data and programs. The computer system 40 communicates with the system controller 60 over a high-speed serial data communications link 54.
[0048] The system controller 60 also comprises a number of modules, which communicate with each other through a backplane 62. The modules of system controller 60 comprise a CP module 64, a pulse generator module 66, a transceiver module 68, a memory module 70 and an array processor module 72. The pulse generator module 66 communicates with the operator console 20 over a serial data communications link 74.
[0049] The gradient amplifier system 80 comprises Gx, Gy and Gz gradient amplifiers 82 to 86 respectively. The gradient amplifiers 82 to 86 receive input gradient pulse data from the system controller 60 and generate output gradient pulses that are conveyed to the MRI machine 120. [0050] The RF coil control circuit 100 includes an output RF amplifier
102, an input RF preamplifier 104 and a transmit/receive (T/R) switch 106. The output RF amplifier 102 and input RF preamplifier 104 communicate with the transceiver module 68 of the system controller 60. The T/R switch 106 is coupled to the MRI machine 120 and to the RF amplifier 102 and RF preamplifier 104.
[0051] The MRI machine 120 includes a cryostat 121 having a bore 122 to receive a patient P supported on table 123. A magnet assembly 124 and RF coils 126 are disposed within the MRI machine 120. The magnet assembly 124 includes a polarizing electromagnet 128 to generate a uniform static polarizing magnetic field B0 and gradient coils 130 that are responsive to the output gradient signals generated by the gradient amplifiers 82 to 86. Each gradient coil 130 is associated with a respective one of the gradient amplifiers. The RF coils 126 are coupled to the T/R switch 106. [0052] In addition to the above components, the MRI system 10 comprises a physiological acquisition controller 140, a scan room interface circuit 142 and a patient positioning system 144. The physiological acquisition controller 140 is coupled to the pulse generator module 66 and to the MRI machine 120. The scan room interface circuit 142 is coupled to the pulse generator module 66, the patient positioning system 144 and the MRI machine 120. The patient positioning system 144 is also coupled to the MRI machine 120. The physiological acquisition controller 140 receives signals from a number of different sensors connected to the patient P, such as ECG signals from electrodes attached to the patient, and conveys the signals to the pulse generator module 66. The scan room interface circuit 142 receives input from various sensors associated with the condition of the patient and the magnet assembly 124 and conveys the signals to the pulse generator module 66. The patient positioning system 144 receives commands from the scan room interface circuit 142 and in response moves the patient P within the MRI machine 120 to the desired location for the scan.
[0053] The general operation of the MRI system 10 will firstly be described for ease of understanding. During imaging, the patient P within the MRI machine 120 is subjected to a uniform static polarizing magnetic field B0 produced by the polarizing electromagnet 128. RF pulses are then generated by the RF coils 126 in a particular sequence and are used to scan target tissue of the patient. MRI signals radiated by excited nuclei in the target tissue in the intervals between consecutive RF pulses are sensed by the RF coils 126. During this MRI signal sensing, the polarizing magnetic field is altered by the gradient coils 130 in response to received output gradient data thereby to position encode acquired MRI signals. [0054] The sequence of RF pulses used to scan the patient P is generated by the RF coils 126 in response to pulse sequence data received from the pulse generator module 66 of the system controller 60 via the transceiver module 68 and RF coil control circuit 100. The pulse sequence data determines the timing, strength and shape of the RF pulses in the pulse sequence as well as the MRI signal acquisition window. The RF sequence data is generated by the pulse generator module 66 in response to scan commands received from the operator console 20 via the data communications link 74. [0055] When an RF pulse is to be applied to the target tissue, the RF coil control circuit 100 is conditioned to a transmit mode by the pulse generator module 66. In the transmit mode, the T/R switch 106 couples the output RF amplifier 102 to the RF coils 126. RF pulse data generated by the pulse generator module 66 is converted into an RF pulse via the transceiver module 68 and RF amplifier 102 and applied to the RF coils 126. [0056] The pulse generator module 66 also generates gradient data in response to the scan commands received from the operator console 20 via the data communications line 74 and conveys the gradient data to the gradient amplifier system 80. The gradient data determines the timing and shape of the output gradient pulses generated by the gradient amplifiers 82 to 86 that are applied to the gradient coils 130 during scanning. [0057] During MRI signal sensing in the MRI signal acquisition window, the pulse generator module 66 conditions the RF coil control circuit 100 to a receive mode. In the receive mode, the T/R switch 106 couples the input RF preamplifier 104 to the RF coils 126. [0058] The MRI signals radiated by excited nuclei in the target tissue are sensed by the RF coils 56 and conveyed to the transceiver module 68 via the T/R switch 106 and input RF preamplifier 104. The amplified MRI signals are in turn demodulated, filtered and digitized by the transceiver module 68 and then transferred to the memory module 70.
[0059] After a scan of the target tissue is completed, an array of raw k- space data is stored in the memory module 70. The array processor 72 Fourier transforms the raw k-space data into an array of image data that is conveyed through the serial data communication link 54 to the computer system 20 where it is stored in the disk memory 50. In response to commands received from the operator console 20, the image data may be archived on the tape drive 52, or it may be further processed by the image processor 44 and conveyed to the operator console 20 for presentation on the display 26. [0060] Figure 2 is a cutaway view of the MRI machine 120 and illustrates the spatial positioning of the polarizing electromagnet 128, RF coils 126, and gradient coils 130 within the MRI machine 120.
[0061] The system and method described herein provide increased specificity in magnetic resonance (MR) molecular imaging by utilizing an auxiliary magnetic field to modify the strength of the main polarizing magnetic field as a function of time in an otherwise standard MRI machine. The response in relaxivity of activated contrast agents to the auxiliary magnetic field allows for improved imaging of activated contrast agents within an MR image. [0062] Contrast-enhanced MRI can generally be categorized as either positive or negative contrast. In positive contrast, image intensity increases at sites of MR contrast agent accumulation as a result of the dominating effect of a decreased longitudinal relaxation time Ti. In negative contrast, image intensity decreases at sites of MR contrast agent accumulation as a result of the dominating effect of a decreased transverse relaxation time T2 (3). For illustrative purposes, the system and method will be described using activatable T1 contrast agents.
[0063] The strength of a Ti contrast agent can be described by its longitudinal relaxivity, n (s"1 mM"1); the larger the relaxivity n, the greater its efficiency at increasing the longitudinal relaxation rate (R? = 1 / Ti) of surrounding tissues and the greater its ability to enhance contrast in T1 weighted MR images. The longitudinal relaxation rate [R1) of a tissue which has taken up a Ti contrast agent of concentration [CA] and relaxivity n can be written as ^1 = * ,Unenhanced + rχ [CA] where i?1Unenhanced signifies the relaxation rate of unenhanced tissue at a particular polarizing magnetic field strength Bo. [0064] The rate of molecular tumbling of a contrast agent in tissue is a factor in determining the relaxivity, n (4). Rapidly tumbling molecules exhibit lower relaxivities (typically < 10 s"1 mM~1) that decline gradually with increasing magnetic field strengths above 0.5 T. Activatable contrast agents are designed to bind more specifically and strongly to certain proteins or classes of proteins or other macromolecular or cellular entities. Upon binding, the resulting decreased tumbling rate has been shown to produce a dramatic increase in relaxivity r\ at low magnetic field strengths (e.g. less than about 0.5 T), with relatively little enhanced relaxivity at higher field strengths (e.g. above 3 T).
[0065] Vasovist or MS-325 (Bayer Healthcare Pharmaceuticals,
Gadofosveset trisodium) is one particular example of a gadolinium chelate of similar size to conventional Gd-DTPA. By virtue of the addition of a lipophilic diphenylcyclohexyl group, this molecule shows strong non-covalent binding to human serum albumin (HAS) (5,6). In the presence of human serum albumin, the bound form of this contrast agent demonstrates an increase of relaxivity by approximately an order of magnitude at 30 Mhz, and approximately four-fold at 60 MHz. The relaxivity curves of Vasovist in the presence and absence of human serum albumin and rabbit serum albumin are shown in Figure 3 (7). In another example, the contrast agent bis-δ-HT-DTPA(Gd) has been developed as a "sensor" of the enzyme myeloperoxidase (8). In the presence of active myeloperoxidase, this contrast agent converts from a monomeric form with minimal protein binding characteristics and relaxivity similar to that of Gd-DTPA, to an oligomeric form with stronger protein binding affinity, leading to enhanced relaxivity. Another gadolinium-based contrast agent EP-2104R (Epix Pharmaceuticals), is currently in clinical trials (9). This contrast agent will selectively bind to fibrin, a significant component of blood clots (thrombi). Upon binding, contrast agent EP-2104R demonstrates a 2.3-times increase in relaxivity at a magnetic field strength equal to 1.5 T. [0066] These three examples of gadolinium-based contrast agents represent the promise of activatable MRI contrast agents, but also illustrate a limitation of this class of agents. That is, the activation-induced relaxivity enhancement may be relatively modest, especially at clinical magnetic field strengths of 1.5 T or 3 T. As a result, it may be difficult to separate intensity enhancement due to the presence of the activated contrast agent from intensity enhancement due to the presence of larger amounts of the non-activated contrast agent.
[0067] To characterize the efficacy of an activatable contrast agent, the relaxivity enhancement ratio, that is the ratio of the activated relaxivity to the inactivated relaxivity can be defined. For Vasovist at a magnetic field strength equal to 1.5 T, the relaxivities in the presence and absence of albumin are 19 s"1 mM'1 and 5.2 s"1 mM'1 respectively, resulting in a relaxivity enhancement ratio of 3.7. From Figure 3 it can be seen that the Vasovist relaxivity enhancement ratio peaks in the vicinity of a magnetic filed strength equal to 0.5 T, and falls quickly for magnetic field strengths above that value. [0068] The subject system and method can distinguish between signal intensities produced by tissues containing activated contrast agent from other sources of signal intensity, using an approach termed delta relaxation enhanced MR (DREMR) (10). DREMR is an MRI method that produces image contrast related to the dependence of relaxation rate upon the strength of the applied polarizing magnetic field as a means to differentiate the activation (binding) state of a targeted contrast agent, where an activated contrast agent demonstrates magnetic field dependence while an inactivated contrast agent does not. [0069] The DREMR approach finds its roots in field-cycling relaxometry imaging methods used by Carlson et al. (11) as a means to differentiate biological tissues. Carlson outfitted a 64 mT whole-body MRI with a pulsed electromagnet insert in order to modulate the strength of the main polarizing magnetic field during an imaging experiment. Carlson was able to show that at low magnetic field strengths the R1 profiles of biological tissues contained features such as cross relaxation peaks and quadruple dips (12). [0070] While Carlson used low-field R1 field variations to identify biological tissues, the system and method described herein utilize the relative lack of R1 field dependence of tissues (13, 14) at higher magnetic field strengths (for example, magnetic field strengths greater than about 0.5 T) to suppress signals from both unenhanced tissues and tissues enhanced by an inactivated contrast agent probe. [0071] Defining R1 ' and ri as the partial derivatives of R1 and n with
' ' ' r i respect to the polarizing magnetic field S0 results in R1 = fl,Unenhanced + η * [CA\ . Applying the approximation that fi/unenhanced ~ 0 for magnetic fields above 1.0 T, results in the expression^ » η * [CA\ . This simple relation shows that the rate of change of the longitudinal relaxation rate (Ri) depends almost exclusively on the rate of change of contrast agent relaxivity {ri) with magnetic field. While activated contrast agents demonstrate high values of ri, inactivated contrast agents have ri values close to zero (Figure 3). For Vasovist, the relaxivity slope enhancement ratio (ratio of activated ri to inactivated ri) is 90 at a magnetic field strength equal to 1.5 T. This represents a 25-fold increase over the absolute relaxivity enhancement ratio of 3.7 mentioned above. The high specificity of DREMR enhancement is not specific to Vasovist but applies to any T1 contrast agent that undergoes binding to large molecules (15). [0072] Transforming R1 ' into image contrast requires the ability to dynamically vary the strength of the main polarizing magnetic field in an MRI system. Access to such platforms is limited to a handful of sites worldwide (16- 18). A more accessible and convenient approach described herein, involves providing conventional MRI machines with the ability to generate an auxiliary magnetic field (ΔB) to enable variable polarizing magnetic field operation. One such approach involves providing the MRI machine with an electromagnetic coil insert (ΔB insert) to enable variable polarizing magnetic field operation. Another approach involves reprogramming a gradient coil within the MRI machine to enable variable polarizing magnetic field operation. Still another approach involves providing the MRI machine with a modified gradient coil to enable variable polarizing magnetic field operation.
[0073] The ΔB auxiliary magnetic field is applied during a relaxation portion of an MRI pulse sequence. For convenience, the ΔB magnetic field is applied during the longitudinal relaxation portions (T1) of the MRI pulse sequence where extremely high stability and homogeneity are not necessary. The main polarizing magnetic field is not altered by the ΔB auxiliary magnetic field during actual signal sensing or any RF pulse application. This means that the normal RF transmit/receive chain can be used without modification. In the following paragraphs, the theory and an experimental demonstration of DREMR are presented, using a small-bore actively-shielded field-cycling electromagnet within an otherwise conventional 1.5 T clinical MRI machine. [0074] Various methods can be employed to generate DREMR contrast.
The simplest method involves the weighted subtraction of two Ti weighted images, each image acquired with a slightly different MRI pulse sequence. These MRI pulse sequences, referred to as the T1+ and T1. sequences, both resemble Ti weighted sequences; however, in the T1+ sequence a magnetic field increasing ΔB auxiliary magnetic field pulse is applied during longitudinal relaxation, while in the T1. sequence a magnetic field decreasing ΔB auxiliary magnetic field pulse is used. In Figure 4, the Ti+ and T1. sequences are shown. Each pulse sequence contains a relaxation portion where the static polarizing magnetic field strength (B0) is either increased or decreased by an amount ΔB, as well as a self-contained signal sensing or acquisition portion, which may be a conventional imaging sequence such as, spin-echo, fast spin-echo, etc. In this example a spin-echo signal acquisition portion is shown.
[0075] On the final line of Figure 4 the longitudinal magnetization of two theoretical tissues is shown. The R1 magnetization rate of the tissue represented by the solid curve is nearly independent of magnetic field strength and therefore relaxes identically for both the T1. and T1+ sequences. However the R1 magnetization rate of the tissue represented by the dashed curve is highly dependent upon the strength of the magnetic field; increasing at lower magnetic field strengths and decreasing at higher magnetic field strengths. Subtraction of the images produced by the T1. and T1+ sequences would result in an image where the only intensity would be due to the magnetic field dependent tissue (dashed curve). The other tissue would be completely suppressed (solid curve). [0076] The following analytic treatment is provided to help describe this method. To simplify the analytic treatment it is assumed that each relaxation portion begins with a saturation RF pulse to eliminate any preexisting longitudinal magnetization; however, other initialization states could be used in a similar analysis. The effect of finite ramping times for the ΔB auxiliary magnetic field pulse will be ignored. Starting at Curie's Law, the steady state longitudinal magnetization (M0) is proportional to the amplitude of the applied magnetic field. Following the completion of a ΔB auxiliary magnetic field pulse of duration fo the longitudinal voxel magnetization (Mz) is equal to Mo-exp(i-ivRf)- Besides effecting R1, modification of the polarizing magnetic field B0 results in the longitudinal voxel magnetization Mz being reduced by a factor of (B0 - Δβ) / B0 by the negative ΔB auxiliary magnetic field pulse, and increased by a factor of (Bo + Δ6) / Bo by the positive ΔB auxiliary magnetic field pulse. In the following, longitudinal magnetization formulae the + and - subscripts on M2 will indicate whether the longitudinal voxel magnetization M2 was formed during a positive or negative ΔB auxiliary magnetic field pulse. R1. will indicate the longitudinal relaxation rate of the sample at the reduced polarizing magnetic field strength of B0 - Δβ, while R1+ indicates the R1 at an increased polarizing magnetic field strength. Note that R1. may be greater than R1+. The longitudinal voxel magnetization following negative and positive ΔB auxiliary magnetic fields are expressed by Equations [1] and [2] below:
Figure imgf000018_0001
Mz+ = M0 .^±M[l -exp(-V*/+)]
B° [2]
[0077] Image voxel intensity is determined by the combined actions of the signal acquisition module, MRI machine signal detection hardware, and console software. For simplicity it will be assumed that the final image intensity is a product of the actual voxel magnetization (M2), and a single positionally dependent term, k, that incorporates proton density, RF coil homogeneity, transverse relaxation time, and any other scaling factors. The resulting image intensity (absolute value) in each pixel l{x, y) is then related to voxel magnetization and expressed as l(x, y) = k(x, y, r) M^r). Forming the DREMR image requires taking the weighted difference of the /. and /+ images. Due to the different equilibrium magnetization introduced by the perturbation magnetic field, the image magnitudes /. and /+ must be normalized prior to subtraction:
[0078] If the assumption is made that Ri is constant in the vicinity of B0 then it is possible to approximate the resulting image intensity by the following expression, wherein ARi is the absolute change in Ri from Bo to Bo ± Δβ:
/Sub « 2k - M0 - sinh(/Δ - AR1 ) - exp(-tA R1 ) [4]
[0079] There are two non-linear terms in Equation 4, namely the hyperbolic sine and exponential decay functions. The hyperbolic sine term, though non-linear, is responsible for the distinctive contrast produced by this method. It indicates that difference in intensity between voxels in the final DREMR image will be related to the Ri values of those voxels. [0080] The exponential decay function results in image shading when the longitudinal relaxation time tA is set too long and the voxel magnetizations of the /. and /+ images begin to saturate. This is comparable to using a TR much longer than Ti when taking a T1 weighted image. If fΔ is chosen so that the maximum product of t& Ri is less than 0.2, then maximum shading is limited to at most 20 percent. In the same way, if fo is chosen so that the maximum product of tϊΔRi is less than 0.5 then nonlinearity effects are limited below 5%. Equation 5a shows that with the appropriate choice of fo image intensity becomes linear with ARi. Equation 5b expresses the result more explicitly with ARi replaced by the product of Ri and ΔB; that is, the slope of Ri multiplied by the strength of the magnetic field shift: ISϋh * 2k - M0 -tA - AR^ [5a] /Sub » 2k - M0 - tli - AB - R, [5b]
[0081] This is the simplest implementation of DREMR. With this implementation, it is possible to produce image intensities that depend on the change in R1 rather than in R1 itself. Activatable contrast agents of the types described herein all produce major changes in R1 ' upon activation, even if the enhancement in Ri is much smaller. This mathematical basis for one implementation of DREMR illustrates its potential application to the specific imaging of activatable MRI contrast agent probes. [0082] DREMR results in a reduction of signal to noise ratio (SNR). Because of the restrictions placed previously, that is ^ R1 < 0.2, the SNR of the constituent images, /. and /+, after normalization can be approximated as k-Moih Ri/o where σ is uncertainty in the images after normalization. Dividing Equation 5b by σ gives the SNR of the DREMR image. This result can be written in terms of the SNR of the source images as: SNRSab ^ 42 - AB - R, /R1 - SNR [6]
[0083] Equation 6 again involves an approximation; it is assumed the magnetic field shifts about Bo are small enough such that the uncertainties of the /. and /+ images are identical. When the magnetic field shifts are larger, the SNR equation must take into account the different uncertainties in each image. [0084] For an R/-ΔB (AR1) of 1 s"1 and an R1 of 10 s~\ the SNR of the
DREMR image drops to 14% of the SNR of the source image. Beyond simply gauging the loss in SNR, Equation 6 illustrates that the maximum SNR would be produced by contrast agents that demonstrate a sharp change in r-i (large r/) for a small value of o . Evaluation of the ril r? of a molecular probe may provide a basis for evaluating which molecular probes would benefit from DREMR contrast.
[0085] This derivation has outlined the most basic method to produce
DREMR contrast. Other more complicated methods could certainly be applied. A double subtraction method for example could utilize several inversion pulses as well as several ΔS auxiliary magnetic field pulses to achieve DREMR contrast without subtraction. [0086] The DREMR approach is now illustrated with reference to the following examples that provide experimental and computer simulated results. Example 1
[0087] To demonstrate the feasibility of the DREMR approach, the contrast agent Vasovist (MS-325) was imaged in the presence and absence of rabbit serum albumin (RSA). As shown in Figure 3, Vasovist preferentially binds to albumin, producing moderate enhancement in the inactivated state and higher enhancement in the activated state. The particular choice of agent/protein pair was based by the availability of the contrast agent and its well-documented relaxivity mechanisms, rather than any specific clinical or research interest in albumin.
[0088] An MRI phantom (see Figure 5a) was constructed that held two columns of six rows of glass tubes; each tube 3 cm in length with a 0.4 ml_ capacity. The sample tubes in the left column were filled with 0.01 M phosphate buffered saline (PBS) (NaCI 0.138M, KCI 0.0027M, pH 7.4 at 25 0C). The right column of sample tubes held a solute of rabbit serum albumin (Sigma-Aldrich, batch 104K7560, agarose gel electrophoresis) in PBS. The albumin, purchased as a lyophilized powder, was dissolved in PBS, at a 4.5% weight to volume ratio resulting in ~0.67mM concentration. Vasovist (0.25 mmol/mL) was added in equal concentration to both columns to achieve sample concentrations of 0, 10, 20, 40, 80 and 160 μM as a function of descending rows. [0089] Imaging was performed on a Sigma LX 1.5 T clinical MRI machine
(General Electric Healthcare), equipped with an actively shielded electromagnetic ΔB insert (19). The ΔB insert, designed to generate ± ΔB auxiliary magnetic field pulses, had an efficiency of 0.7 mT/A, weighed approximately 150 kg and was designed to facilitate the imaging of animals as large as rabbits. The ΔB insert was driven by a pair of Techron 8607 gradient amplifiers arranged in a master/slave series configuration enabling a maximum bipolar output of 100A. Input waveforms to the gradient amplifiers were generated by National Instruments data acquisition hardware and controlled via software written in LabView (National Instruments, version 8.2). Waveform synchronization between the data acquisition device and the MRI console was achieved by means of the 'scope trigger' output of the console electronics. [0090] The following spin-echo pulse sequence parameters were used for all images that were combined to produce the final DREMR image: 150 ms pulse repetition time, 10 ms echo time, 31 kHz bandwidth, 8 cm field of view and 10 mm slice thickness. The scan time was 24s for each image. For each row of /c-space, 70 mT AB auxiliary magnetic field pulses were applied for 100-ms intervals. The ΔB auxiliary magnetic field pulses were timed to end 10 ms prior to image acquisition to give both the polarizing magnetic field and amplifiers time to stabilize.
[0091] For T1+ images the polarizing magnetic field was increased by 70 mT during the relaxation portion of the MRI pulse sequence. Likewise for T1. images the polarizing magnetic field was decreased by the same amount. Ten pairs of T1+ and T1. weighted images were acquired for the samples held at 21 0C. Acquisitions of T1+ and T1. enhanced images were interleaved to minimize heating of the amplifiers. The positively enhanced images were then averaged into a single dataset, as were the negatively enhanced images. The resulting two datasets were normalized and the absolute difference taken to produce contrast related to the magnetic field dependence of R1. Unlike in the theoretic treatment a saturation pulse was not applied prior to the ΔB auxiliary magnetic field pulse. Standard Ti weighted spin-echo images using the same MRI pulse sequence parameters were acquired for comparison.
[0092] Figure 5b shows the standard T1 weighted spin-echo image of the samples. As expected, the intensity of both columns increased from top to bottom with concentration of Vasovist. The measured average intensity within each sample is plotted in Figure 6a. The error bar on each data point indicates the standard deviation of voxel intensity throughout the corresponding sample. Both sets of samples, albumin solution and PBS, demonstrated significant dependence on Vasovist concentration. Because the range of intensities of the albumin samples (A) were not clearly separated from those of the PBS samples (•) but in fact were appreciably overlapped, it is clear that without prior knowledge of Vasovist concentrations, it would not be possible to differentiate the albumin-containing sample from PBS-only samples based on T1 weighted image intensity alone.
[0093] Figure 5c illustrates the absolute difference of the ± ΔS auxiliary magnetic field datasets. The figure shows the entire dynamic range without thresholding. The average intensity from each of the samples is plotted in Figure 6b. The standard deviation of voxel intensities within each sample is again expressed as an error bar. While the image intensity of albumin samples continued to demonstrate dependence on Vasovist concentration, the PBS samples were significantly suppressed. The intensities of all PBS samples were suppressed well below the intensity of the weakest albumin-loaded sample, which had only a 10μM Vasovist concentration. Thus a substantially increased specificity to albumin was obtained through DREMR imaging. [0094] Intensity variations in the DREMR image were seen to increase by a factor of 2.5 times those of the T1 weighted image as indicated by the larger error bars in Figure 6b compared to Figure 6a. This was due to the combined effects of SNR loss and introduction of subtraction artefacts. Subtraction artefacts appear as a mottling across the samples and are due to instabilities in the polarizing magnetic field Bo during image acquisition; instabilities most likely introduced by rapid switching of the ΔB insert. Subtraction artefacts were localized to positions having significant image intensity in the constituent images whereas noise increased across the entire image. Even with active shielding, minor inductive coupling between the ΔB insert and the MRI machine has the potential to produce eddy currents in the cryostat and superconductive windings of the polarizing electromagnet. These eddy currents could destabilize the main polarizing magnetic field, causing minor slice selection errors and errors in the RF tip angle. To counter this potential problem, the ΔB insert was used as an active shim during image acquisition. Example 2 [0095] The embodiments described in this Example allow for generation of an auxiliary magnetic field, without the need for the auxiliary electromagnetic insert described in Example 1. The embodiments described in this Example involve either an unmodified MRI system or an MRI system comprising a modified gradient coil system. The modified gradient system may be used to produce both linearly varying and uniform polarizing magnetic fields across the imaging region.
[0096] In Figure 7 one embodiment is shown in which a standard spin- echo pulse sequence has been modified to include gradient-induced magnetic field pulses during the relaxation portion of the MRI pulse sequence. The choice of spin-echo pulse sequence is consistent with Figure 4 which used a spin-echo pulse sequence to generally illustrate the timing of ΔB auxiliary magnetic field generation. Figure 7 shows that all three gradient coils (Gs, Gp, and Gf, also known as Gz, Gx and Gy, respectively) are applied at the same time to generate ΔB auxiliary magnetic field pulses throughout time TΔ. TΔ occurs within the T1 relaxation portion of the pulse sequence. (TΔ in Figure 7 and tΔ in Figure 4 are used interchangeably to designate the ΔB auxiliary magnetic field pulse duration). In conventional MRI none of the gradient coils pulse during a relaxation portion of the MRI pulse sequence, as represented by the dashed lines in Figure 7. Conventionally, gradient coils are only pulsed during an image acquisition portion of the MRI pulse sequence. For simplification, the reversal of the ΔB auxiliary magnetic field as shown in Figure 4(b) is not shown in Figure 7. [0097] When an MRI machine, equipped with a traditional gradient coil set is used, the target being imaged may require placement away from iso- center (Figure 8). The strength of the ΔB magnetic field shift produced by the unmodified gradient coil is at its maximum at the very edge of the imaging region, and therefore to optimize contrast the target being imaged may be placed at the edge of the imaging region. [0098] In another embodiment, one or more of the gradient coils of the
MRI machine are modified to generate a substantially uniform non-zero auxiliary magnetic field across the imaging region image during the relaxation portion of the MRI pulse sequence. Therefore, the positioning of the target with respect to the iso-center is not needed to optimize contrast. Figure 9 shows a schematic of a typical unmodified longitudinal gradient coil connected to a set of amplifiers. The typical longitudinal gradient coil can be thought of as two distinct coils electrically wired in series. By electrically separating the two halves of the gradient coil and attaching each half to a separate amplifier, each half of the gradient can be independently controlled.
[0099] When both amplifiers cause current to flow with the same polarity
(Figure 10), the modified gradient coil behaves in the typical gradient coil fashion and a linearly varying magnetic field is produced for MR image formation (plotted as 'Gradient Mode' in Figure 12). When the amplifiers cause current with opposite polarities to flow (Figure 11) the modified gradient coil behaves as a ΔB coil, in that it generates a substantially uniform auxiliary magnetic field across the imaging region (plotted as 'ΔB mode' in Figure 12), ideally producing a magnetic field shift that is invariant with position.
[00100] In its intended operation, a modified gradient coil will produce a constant auxiliary magnetic (ΔB) field during the relaxation portion of the MRI pulse sequence (Figure 7) and a varying magnetic (gradient) field during the imaging portion of the MRI pulse sequence. Thus, a single gradient coil can be used to create the magnetic field shift during the relaxation portion of the MRI pulse sequence for contrast enhancement, and the varying magnetic field shift required for acquiring spatial MRI image formation. [00101] Figures 13 and 14 show the wire pattern for one particular embodiment of a modified gradient coil. Current direction is indicated by the color coding of the wire; black indicates that current flow is parallel to the x-axis and grey indicates anti-parallel current flow. In Figure 8, the gradient coil behaves like a traditional gradient coil. In Figure 9 the current direction is reversed in the top half of the coil and the modified gradient coil behaves like a Δβ coil. [00102] In some embodiments similar approaches may be used to modify the transverse (x and y) gradient coils to allow dual operation as either a conventional gradient coil or a AB coil. Current direction is indicated by the color coding of the wire; black lines indicate current flow parallel to the y-axis and grey lines indicates current flow anti-parallel to the y- axis. Figure 15 shows the wire pattern of a particular embodiment of a transverse gradient coil when used in gradient mode. When the polarity of current is changed in half of the gradient coil only (Figure 16), the coil acts as a Δβ coil and produces a uniform magnetic field profile.
[00103] Embodiments that provide conventional gradient coils with the target in the iso-center, conventional gradient coils with the target offset from the iso-center, and a modified longitudinal gradient coil with the target in the iso- center were analyzed using computer simulations. As a comparator, a standard Ti weighted image was also produced.
[00104] For each of the computer simulations (shown in Figures 17, 18, 20 and 22) the target being imaged is a tumour (represented by a circle) that is surrounded with interstitial fluid (each quadrant representing a distinct concentration of Vasovist). The tumor contains the protein albumin, which is not found in the surrounding fluid. Albumin binds to the contrast agent Vasovist. Vasovist is used to enhance the tumor, but due to leaky vasculature also enhances the interstitial fluid. Inside the tumor the concentration of Vasovist is 20 μM, while outside the tumor the concentration of Vasovist varies from 20 to 160 μM as shown in Figure 17. The tumour and interstitial fluid Vasovist and albumin concentrations are identical for each of Figures 17, 18, 20 and 22. [00105] As a comparative example, a standard Ti weighted image of the tumour is shown in Figure 17. Figure 17 shows that standard Ti weighting is insufficient to enhance the tumour over the interstitial fluid.
[00106] DREMR can be used to create image contrast that preferentially enhances locations where the protein albumin has bound the Vasovist contrast agent (e.g. inside the tumour). DREMR uses an auxiliary magnetic field shift to produce the unique contrasts. In these computer simulation examples the auxiliary magnetic field, ΔB, is achieved by the longitudinal gradient coil of the MRI system.
[00107] Figure 18 shows a simulated DREMR image of the tumour. The DREMR contrast has been created by applying a linearly varying magnetic field across the image. During the relaxation portion of each pulse sequence, the ΔB auxiliary magnetic field increases from -1 OmT on the left to 10mT on the right to produce a first T1 weighted image. The ΔB auxiliary magnetic field is then reversed to produce a second Ti weighted image. Subtraction of the first and second Ti weighted images produces the DREMR image. In the conventional method used to produce the image in Figure 17 no subtraction occurred and no ΔB auxiliary magnetic field was generated during the relaxation portion of the MRI pulse sequence. [00108] Figure 19 shows the setup for Figure 18. The tumour is located at the iso-center where the gradient magnetic field changes from positive to negative. As a result of DREMR performed in this setup, and as seen in Figure 18, the background of the tumour has been suppressed, but the cost to image quality is quite high. More specifically, Figure 18 shows that in the middle of the tumour (circle) there is no contrast between the tumour and the background, as the middle of the tumour coincides with the iso-center. [00109] Figure 20 shows a simulated DREMR image where the sample has been shifted off-axis, but is otherwise the same setup as used for Figure 18. The ΔB auxiliary magnetic field increases from 2OmT on the left to 4OmT on the right to produce a first Ti weighted image. The ΔB auxiliary magnetic field is then reversed to produce a second T1 weighted image. Subtraction of the first and second Ti weighted images produces the DREMR image. Figure 20 shows a significant improvement over Figures 17 and 18; however some shading still exists across the tumour. Further improvements in image quality can be achieved as a function of averaging and/or offset positioning from multiple axes. [00110] Figure 21 shows the setup for Figure 20. The tumour has been placed off-axis where the ΔB auxiliary magnetic field generated by the gradient coil during the relaxation portion of the pulse sequence is consistently positive (shown), or consistently negative when the ΔB auxiliary magnetic field is reversed (not shown).
[00111] Figure 22 shows a simulated DREMR image where the sample is at iso-center and a modified gradient coil as shown in Figures 10 to 14 has been used to generate a substantially uniform ΔB auxiliary magnetic field at all points across the imaging region. The ΔB auxiliary magnetic field of 4OmT is used to produce a first Ti weighted image. The ΔB auxiliary magnetic field is then reversed at -4OmT to produce a second Ti weighted image. Subtraction of the first and second T1 weighted images produces the DREMR image. The image shown in Figure 22 benefits from a lack of shading across the tumour, thereby increasing contrast over the background interstitial fluid. Furthermore, this image quality can be produced independent of the positioning of the target sample, including positioning at the iso-center. [00112] Figure 23 shows the setup for Figure 22. The tumour is placed at the iso-center similar to the setup for Figure 18, but because the modified gradient coil generates a substantially uniform ΔB auxiliary magnetic field across the target sample an improved image is obtained in Figure 22 compared to Figures 17, 18 and 20. [00113] The software application used to drive the electromagnetic ΔB insert, the gradient coil, or the modified gradient coil may run as a stand-alone application or may be incorporated into other available applications to provide enhanced functionality to those applications. The software application may comprise program modules including routines, programs, object components, data structures etc. and may be embodied as computer readable program code stored on a computer readable medium. The computer readable medium is any data storage device that can store data, which can thereafter be read by a computer system. Examples of computer readable media include for example read-only memory, random-access memory, CD-ROMs, magnetic tape and optical data storage devices. The computer readable program code can also be distributed over a network including coupled computer systems so that the computer readable program code is stored and executed in a distributed fashion. [00114] In one particular embodiment, the method and system take advantage of the change in longitudinal relaxivity vs. field strength, i.e. the relaxivity slope, to generate selective image contrast occurring when a contrast agent binds to a given target molecule. In other embodiments, variations other than the slope may be examined. [00115] The system and method have been described in respect of embodiments relating to Ti relaxation times and Ti contrast agents. In other embodiments, the system and method may be adapted to produce image contrast related to the magnetic field dependence of T2 contrast agents. [00116] The system and method described herein is readily applicable to any type of MRI machine, for example bore or gap-type MRI machines. [00117] The polarizing magnetic field B0 generated by the MRI machine may be of any desired strength, but will typically be greater than 0.2 T. [00118] The system and method have been described with respect to embodiments where an auxiliary magnetic field is provided by either an insert or a gradient coil. It will be recognized that various MRI pulse sequences may be combined with gradient pulses during the relaxation portion of the pulse sequence to produce image contrast. Any number of gradient coils may be used to generate the ΔB magnetic field during the relaxation portion of the pulse sequence, for example one gradient coil may be used alone or multiple gradient coils may be used in combination. Any conventional gradient coil can be reprogrammed or modified in accordance with the system and method described herein, including for example flat or planar gradient coils. [00119] When offsetting a target from the iso-center, the target may be offset along one or more of the x, y and z axis of a Cartesian coordinate system. [00120] The above-described embodiments are intended to be examples and alterations and modifications may be effected thereto, by those of skill in the art, without departing from the scope of the invention which is defined by the claims appended hereto.
[00121] REFERENCES
1. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001 ;219(2):316-333.
2. Nahrendorf M, Sosnovik DE, Weissleder R. MR-optical imaging of cardiovascular molecular targets. Basic research in cardiology 2008;103(2):87- 94.
3. Hendrick RE, Haacke EM. Basic physics of MR contrast agents and maximization of image contrast. J Magn Reson Imaging 1993;3(1):137-148.
4. Wood ML, Hardy PA. Proton relaxation enhancement. J Magn Reson Imaging 1993;3(1):149-156.
5. Caravan P, Cloutier NJ, Greenfield MT, McDermid SA, Dunham SU, Bulte JW, Amedio JC, Jr., Looby RJ, Supkowski RM, Horrocks WD, Jr., McMurry TJ, Lauffer RB. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. Journal of the American Chemical Society 2002; 124(12):3152-3162.
6. Henrotte V, Vander Elst L, Laurent S, Muller RN. Comprehensive investigation of the non-covalent binding of MRI contrast agents with human serum albumin. J Biol lnorg Chem 2007;12(6):929-937.
7. Eldredge HB, Spiller M, Chasse JM, Greenwood MT, Caravan P. Species dependence on plasma protein binding and relaxivity of the gadolinium- based MRI contrast agent MS-325. Investigative radiology 2006;41(3):229-243.
8. Nahrendorf M, Sosnovik D, Chen JW, Panizzi P, Figueiredo JL, Aikawa E, Libby P, Swirski FK, Weissleder R. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008; 117(9): 1153-1160.
9. Overoye-Chan K, Koerner S, Looby RJ, Kolodziej AF, Zech SG, Deng Q, Chasse JM, McMurry TJ, Caravan P. EP-2104R: a fibrin-specific gadolinium- Based MRI contrast agent for detection of thrombus. Journal of the American Chemical Society 2008; 130(18):6025-6039.
10. Alford JK. Delta relaxation enhanced MR (dreMR): Theory of T1 -slope weighted contrast. ISMRM. Toronto, Canada; 2008. 11. Carlson JW, Goldhaber DM, Brito A, Kaufman L. MR relaxometry imaging. Work in progress. Radiology 1992;184(3):635-639.
12. Ungersma SE, Matter Nl, Hardy JW, Venook RD, Macovski A, Conolly SM, Scott GC. Magnetic resonance imaging with T1 dispersion contrast. Magn Reson Med 2006;55(6): 1362-1371.
13. Bottomley PA, Foster TH, Argersinger RE, Pfeifer LM. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys 1984;11(4):425-448. 14. Henriksen O, de Certaines JD, Spisni A, Cortsen M, Muller RN, Ring PB. In vivo field dependence of proton relaxation times in human brain, liver and skeletal muscle: a multicenter study. Magn Reson Imaging 1993;11(6):851-856.
15. Zhou X, Caravan P, Clarkson RB, Westlund PO. On the philosophy of optimizing contrast agents. An analysis of 1H NMRD profiles and ESR lineshapes of the Gd(lll)complex MS-325+HSA. J Magn Reson 2004;167(1):147-160.
16. Gilbert KM, Handler WB, Scholl TJ, Odegaard JW, Chronik BA. Design of field-cycled magnetic resonance systems for small animal imaging. Phys Med Biol 2006;51(11):2825-2841. 17. Matter Nl, Scott GC, Grafendorfer T, Macovski A, Conolly SM. Rapid polarizing field cycling in magnetic resonance imaging. IEEE Trans Med Imaging 2006;25(1):84-93.
18. Lurie DJ, Foster MA, Yeung D, Hutchison JM. Design, construction and use of a large-sample field-cycled PEDRI imager. Phys Med Biol 1998;43(7): 1877-1886.
19. Alford J. From static to dynamic: Construction of an actively shielded Bo coil for field-cycled imaging with clinical MR platforms. ISMRM. Toronto, Canada; 2008.
[00122] Documents cited in this specification are herein incorporated by reference.

Claims

What is claimed is:
1. A method for contrast agent enhanced magnetic resonance imaging (MRI) of a target sample, comprising: generating a magnetic field shift in a polarizing magnetic field during a relaxation portion of an MRI pulse sequence and thereafter acquiring an MR image.
2. The method of claim 1 , wherein the magnetic field shift is a substantially uniform shift across an imaging region.
3 The method of claim 1 , wherein the magnetic field shift is spatially varying across an imaging region.
4. The method of claim 3, wherein the magnetic field shift is a linearly varying gradient across the imaging region.
5. The method of claim 3, further comprising offsetting the target sample from the iso-center of a gradient coil.
6. The method of claim 5, wherein the target sample is offset along the longitudinal axis from the iso-center.
7. The method of claim 5, wherein the target sample is offset with respect to more than one axis from the iso-center.
8. The method of claim 1 , wherein the magnetic field shift is generated by a gradient coil.
9. The method of claim 8, wherein the gradient coil generates a substantially uniform magnetic field across an imaging region during the relaxation portion of the MRI pulse sequence.
10. The method of claim 8, wherein the gradient coil generates a varying magnetic field across an imaging region during the relaxation portion of the MRI pulse sequence.
11. The method of claim 9, wherein the gradient coil generates a varying magnetic field across an imaging region during a signal aquisition portion of the MRI pulse sequence.
12. The method of any one of claims 1 to 11 , wherein the MRI pulse sequence is a spin-echo pulse sequence.
13. A method of magnetic resonance imaging comprising: subjecting a sample to polarizing magnetic fields of different strengths and acquiring a scan associated with each polarizing magnetic field; and processing the scans to generate selective image contrast of said sample based on the variation of at least one MR property of the sample in response to the different polarizing magnetic field strengths.
14. The method of claim 13 wherein said subjecting comprises: shifting the strength of a polarizing magnetic field of an MRI machine in more than one direction during a relaxation portion of a pulse sequence and thereafter acquiring an image.
15. The method of claim 14 wherein the timing, magnitude and duration of each polarizing magnetic field shift is chosen to maximize the desired image contrast enhancement.
16. The method of claim 14 or 15 wherein the polarizing magnetic field is shifted in each direction by substantially the same amount.
17. The method of claim 16, wherein the magnetic field shift is generated by a gradient coil of the MRI machine.
18. The method of claim 17, wherein the gradient coil generates a substantially uniform magnetic field across an imaging region during the relaxation portion of the pulse sequence.
19. The method of claim 17, wherein the gradient coil generates a varying magnetic field across an imaging region during the relaxation portion of the pulse sequence.
20. The method of claim 18, wherein the gradient coil generates a varying magnetic field across an imaging region during a signal aquisition portion of the pulse sequence.
21. The method of any one of claims 13 to 20, wherein the pulse sequence is a spin-echo pulse sequence.
22. A magnetic resonance imaging method comprising: performing multiple scans of a subject and generating an image for each scan, each scan being conducted utilizing a different polarizing magnetic field; and processing the images to yield an enhanced contrast image, wherein said performing comprises: shifting the polarizing magnetic field of an MRI machine in one direction during a relaxation portion of a first pulse sequence and thereafter acquiring an image; and shifting the polarizing magnetic field of the MRI machine in an opposite direction during a relaxation portion of a second pulse sequence and thereafter acquiring an image.
23. The method of claim 22 wherein the first shifting comprises subjecting the polarizing magnetic field of the MRI machine to a magnetic field pulse of a first polarity during the relaxation portion of the first pulse sequence and wherein the second shifting comprises subjecting the polarizing magnetic field of the MRI machine to a magnetic field pulse of a second polarity during the relaxation portion of the second pulse sequence.
24. The method of claim 23 wherein the timing, magnitude and duration of each polarizing magnetic field shift is chosen to maximize the desired image contrast enhancement.
25. The method of claim 23 or 24 wherein the polarizing magnetic field is shifted in each direction by substantially the same amount.
26. The method of claim 25, wherein the polarizing magnetic field shift is generated by a gradient coil of the MRI machine.
27. The method of claim 26, wherein the gradient coil generates a substantially uniform magnetic field across an imaging region during the relaxation portion of the pulse sequence.
28. The method of claim 26, wherein the gradient coil generates a varying magnetic field across an imaging region during the relaxation portion of the pulse sequence.
29. The method of claim 27, wherein the gradient coil generates a varying magnetic field across an imaging region during a signal aquisition portion of the pulse sequence.
30. The method of any one of claims 22 to 29, wherein the pulse sequence is a spin-echo pulse sequence.
31. An MRI machine comprising: a housing having a bore in which a subject to be imaged is placed; a polarizing electromagnet accommodated by said housing and generating a generally uniform polarizing magnetic field within said bore; pulse generating coils to generate pulses in a sequence to scan the subject; and gradient coils to encode acquired MRI signals, wherein said gradient coils are futher configured to genate a shift in the polarizing magnetic field during a relaxation portion of the sequence.
32. The MRI machine of claim 31 , wherein the gradient coils generate a substantially uniform magnetic field across an imaging region during the relaxation portion of the sequence.
33. The MRI machine of claim 31 , wherein the gradient coils generate a varying magnetic field across an imaging region during the relaxation portion of the sequence.
34. The MRI machine of claim 33, wherein the gradient coils generate a varying magnetic field across an imaging region during a signal aquisition portion of the sequence.
35. The MRI machine of any one of claims 31 to 34, wherein the sequence is a spin-echo pulse sequence.
PCT/CA2009/001538 2008-10-27 2009-10-27 System and method for magnetic resonance imaging WO2010048708A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/126,253 US9423480B2 (en) 2008-10-27 2009-10-27 System and method for magnetic resonance imaging
US15/166,711 US10663548B2 (en) 2008-10-27 2016-05-27 System and method for magnetic resonance imaging

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10873408P 2008-10-27 2008-10-27
US61/108,734 2008-10-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/126,253 A-371-Of-International US9423480B2 (en) 2008-10-27 2009-10-27 System and method for magnetic resonance imaging
US15/166,711 Continuation US10663548B2 (en) 2008-10-27 2016-05-27 System and method for magnetic resonance imaging

Publications (1)

Publication Number Publication Date
WO2010048708A1 true WO2010048708A1 (en) 2010-05-06

Family

ID=42128153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2009/001538 WO2010048708A1 (en) 2008-10-27 2009-10-27 System and method for magnetic resonance imaging

Country Status (2)

Country Link
US (2) US9423480B2 (en)
WO (1) WO2010048708A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2682775A1 (en) 2012-07-04 2014-01-08 Bruker BioSpin GmbH Field Cycling Method for Magnetic Resonance
CN104122518A (en) * 2013-04-25 2014-10-29 上海联影医疗科技有限公司 Magnetic resonance imaging system and passive shimming device

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009062145A1 (en) * 2007-11-09 2009-05-14 Vista Clara, Inc. Multicoil low-field nuclear magnetic resonance detection and imaging apparatus and method
WO2010048708A1 (en) * 2008-10-27 2010-05-06 The University Of Western Ontario System and method for magnetic resonance imaging
WO2012122462A2 (en) * 2011-03-09 2012-09-13 Thimbletech, Inc. Use of magnetic resonance techniques for molecular detection
WO2016134437A1 (en) * 2015-02-23 2016-09-01 Synaptive Medical (Barbados) Inc. System and method for magnetic resonance coil arrangement
GB2552610B (en) * 2015-02-23 2021-07-07 Synaptive Medical Inc System and method for magnetic resonance coil arrangement
GB2553703B (en) * 2015-03-11 2021-07-21 Synaptive Medical Inc System and method for imaging macrophage activity using delta relaxation enhanced magnetic resonance imaging
US10067203B2 (en) * 2015-10-09 2018-09-04 General Electric Company Energy storage solution for an MRI system
US10718841B2 (en) * 2016-01-14 2020-07-21 Beth Israel Deaconess Medical Center, Inc. System and method for improved homogeneous and inhomogeneous magnetization transfer magnetic resonance imaging
US10969453B2 (en) * 2016-01-22 2021-04-06 Synaptive Medical Inc. Systems and methods for magnetic field-dependent relaxometry using magnetic resonance imaging
US10429463B2 (en) * 2016-06-13 2019-10-01 Toshiba Medical Systems Corporation Quiet MRI with spin echo (SE) or fast spin echo (FSE)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748409A (en) * 1984-12-14 1988-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Imaging magnetic spin resonance method and apparatus
US5363042A (en) * 1993-08-12 1994-11-08 General Electric Company Methods for measurement of longitudinal spin relaxation times in moving liquids
US6662038B2 (en) * 1993-06-07 2003-12-09 Martin R. Prince Method and apparatus for imaging abdominal aorta and aortic aneurysms

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68344A (en) * 1983-04-10 1988-10-31 Yeda Res & Dev Method to eliminate the effects of magnetic field inhomogeneities in nmr imaging
US4577152A (en) 1983-04-11 1986-03-18 Albert Macovski Selective material projection imaging system using nuclear magnetic resonance
FR2579753B1 (en) 1985-03-26 1988-03-25 Thomson Cgr METHOD AND DEVICE FOR NUCLEAR MAGNETIC RESONANCE IMAGING
US4718424A (en) * 1986-08-07 1988-01-12 Stanford University NMR imaging of blood flow by moment variation of magnetic gradients
DE69033071T2 (en) * 1989-02-23 1999-09-23 Toshiba Kawasaki Kk Nuclear spin imaging process
US5144328A (en) 1990-06-20 1992-09-01 Metromedia Company Method for producing an image on a substrate having the same spectral content with front and back illumination
US5304931A (en) * 1991-08-09 1994-04-19 Flamig Duane P Magnetic resonance imaging techniques
DE69326202T2 (en) * 1992-06-29 2000-04-13 Koninkl Philips Electronics Nv Method and device for magnetic resonance imaging
GB9216597D0 (en) 1992-08-05 1992-09-16 British Tech Group Method of obtaining images representing the distribution of paramagnetic material in solution
DE4415393B4 (en) * 1993-06-01 2010-10-14 Siemens Ag A method of generating images in a magnetic resonance imaging apparatus having a spin echo pulse sequence
US5335660A (en) * 1993-08-12 1994-08-09 General Electric Company Magnetic resonance method of measuring kidney filtration rates
JP3393895B2 (en) * 1993-09-13 2003-04-07 株式会社東芝 Magnetic resonance imaging
US5509412A (en) * 1994-08-24 1996-04-23 Wisconsin Alumni Research Foundation Magnetic resonance imaging of blood volume
JP3505294B2 (en) * 1995-03-28 2004-03-08 ジーイー横河メディカルシステム株式会社 MRI equipment
US5684400A (en) * 1995-06-12 1997-11-04 Ge Yokogawa Medical Systems, Limited Diffusion sensitizing imaging method, dynamic imaging method, and MRI apparatus
BR9812716A (en) * 1997-10-02 2000-08-22 Epix Medical Inc Imaging methods for enhanced contrast diagnosis to monitor interventional therapies
EP0958503B1 (en) * 1997-12-08 2010-01-27 Koninklijke Philips Electronics N.V. Method of and device for imaging an object by means of magnetic resonance
US6459922B1 (en) 1999-03-30 2002-10-01 Toshiba America Mri, Inc. Post data-acquisition method for generating water/fat separated MR images having adjustable relaxation contrast
WO2000066180A2 (en) * 1999-04-21 2000-11-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Method for enhancing contrast produced by mri
US6603989B1 (en) * 2000-03-21 2003-08-05 Dmitriy A. Yablonskiy T2 contrast in magnetic resonance imaging with gradient echoes
GB0009353D0 (en) * 2000-04-14 2000-05-31 Nycomed Imaging As Method
US6317620B1 (en) * 2000-05-04 2001-11-13 General Electric Company Method and apparatus for rapid assessment of stenosis severity
KR100383623B1 (en) 2000-12-30 2003-05-14 삼성전자주식회사 Hinge module for portable radiotelephone
US6794869B2 (en) 2001-03-30 2004-09-21 General Electric Company Moving table MRI with frequency-encoding in the z-direction
US6801034B2 (en) 2001-03-30 2004-10-05 General Electric Company Method and apparatus of acquiring large FOV images without slab-boundary artifacts
US6869591B2 (en) * 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
US7835783B1 (en) * 2002-04-22 2010-11-16 The United States Of America As Represented By The Department Of Health And Human Services Magnetic resonance imaging methods and apparatus for time-series motion tracking with inversion recovery compensation
US6963768B2 (en) 2002-05-16 2005-11-08 General Electric Company Whole body MRI scanning with moving table and interactive control
GB0219953D0 (en) 2002-08-29 2002-10-02 Amersham Health R & D Ab An arrangement and a method for providing contrast agents
DE10301497B4 (en) 2003-01-16 2013-12-24 Siemens Aktiengesellschaft Magnetic resonance projection angiography method with continuous table displacement and MRI apparatus for performing the method
JP4342809B2 (en) * 2003-02-14 2009-10-14 株式会社東芝 MRI equipment
US6873153B2 (en) * 2003-07-07 2005-03-29 Yeda Research And Development Co., Ltd. Method and apparatus for acquiring multidimensional spectra and improved unidimensional spectra within a single scan
US7502640B2 (en) * 2004-05-18 2009-03-10 The Board Of Trustees Of The Leland Stanford Junior University Positive contrast MRI of magnetically tagged cells, objects, tissues
US7403810B2 (en) 2004-05-19 2008-07-22 Northwestern University Time resolved contrast-enhanced MR projection imaging of the coronary arteries with intravenous contrast injection
JP5167125B2 (en) 2005-07-08 2013-03-21 ウイスコンシン アラムナイ リサーチ ファウンデーシヨン Limited backprojection reconstruction of undersampled MRI
US7570054B1 (en) * 2006-04-20 2009-08-04 The General Hospital Corporation Dynamic magnetic resonance inverse imaging using linear constrained minimum variance beamformer
CN101454686A (en) * 2006-05-25 2009-06-10 皇家飞利浦电子股份有限公司 Three-dimensional asymmetric transverse gradient coils
GB2459075B (en) * 2006-06-02 2010-12-15 Siemens Molecular Imaging Ltd Estimation of blood input function for functional medical scans
WO2008122899A1 (en) * 2007-04-04 2008-10-16 Koninklijke Philips Electronics N.V. Split gradient coil and pet/mri hybrid system using the same
US8922209B2 (en) * 2008-03-11 2014-12-30 The University Of Western Ontario System and method for magnetic resonance imaging
US20090253983A1 (en) 2008-04-07 2009-10-08 General Electric Company Image based measurement of contrast agents
WO2010048708A1 (en) * 2008-10-27 2010-05-06 The University Of Western Ontario System and method for magnetic resonance imaging
US9013184B2 (en) 2011-07-18 2015-04-21 Siemens Medical Solutions Usa, Inc. MR imaging system for automatically providing incidental findings

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748409A (en) * 1984-12-14 1988-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Imaging magnetic spin resonance method and apparatus
US6662038B2 (en) * 1993-06-07 2003-12-09 Martin R. Prince Method and apparatus for imaging abdominal aorta and aortic aneurysms
US5363042A (en) * 1993-08-12 1994-11-08 General Electric Company Methods for measurement of longitudinal spin relaxation times in moving liquids

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELDREDGE ET AL., INVESTIGATIVE RADIOLOGY, vol. 41, no. 3., March 2006 (2006-03-01) *
K. M. GILBERT ET AL.: "Design of Field Cycled Magnetic Resonance Systems for Small Animal Imaging", PHYSICS IN MEDICINE AND BIOLOGY, vol. 51, 2006, pages 2825 - 2841 *
SHARON UNGERSMA ET AL.: "Magnetic Resonance Imaging with T1 Dispersion Contrast", MAGNETIC RESONANCE IN MEDICINE, vol. 55, 2006, pages 1362 - 1371 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2682775A1 (en) 2012-07-04 2014-01-08 Bruker BioSpin GmbH Field Cycling Method for Magnetic Resonance
US8825132B2 (en) 2012-07-04 2014-09-02 Bruker Biospin Gmbh Field cycling method for magnetic resonance
CN104122518A (en) * 2013-04-25 2014-10-29 上海联影医疗科技有限公司 Magnetic resonance imaging system and passive shimming device

Also Published As

Publication number Publication date
US9423480B2 (en) 2016-08-23
US20110279117A1 (en) 2011-11-17
US20160274208A1 (en) 2016-09-22
US10663548B2 (en) 2020-05-26

Similar Documents

Publication Publication Date Title
US10663548B2 (en) System and method for magnetic resonance imaging
US11047941B2 (en) System and method for magnetic resonance imaging
Thangavel et al. Aqueous paramagnetic solutions for MRI phantoms at 3 T: A detailed study on relaxivities
Duyn MR susceptibility imaging
Ouwerkerk Sodium mri
Matsumoto et al. Electron paramagnetic resonance imaging of tumor hypoxia: enhanced spatial and temporal resolution for in vivo pO2 determination
Alford et al. Delta relaxation enhanced MR: improving activation‐specificity of molecular probes through R1 dispersion imaging
Crémillieux et al. High‐resolution in vivo measurements of transverse relaxation times in rats at 7 Tesla
Shah et al. The z-spectrum from human blood at 7T
Närväinen et al. Z-spectroscopy with alternating-phase irradiation
CN113406544B (en) Magnetic resonance electromagnetic characteristic parameter imaging method and device for human biological tissue
Foltz et al. Principles of magnetic resonance imaging
Rodgers et al. Cardiovascular magnetic resonance: physics and terminology
Storey Introduction to magnetic resonance imaging and spectroscopy
Alzola-Aldamizetxebarria et al. A comprehensive introduction to magnetic resonance imaging relaxometry and contrast agents
Sapkota et al. Characterization of spinal cord white matter by suppressing signal from hindered space. A Monte Carlo simulation and an ex vivo ultrahigh-b diffusion-weighted imaging study
Olsrud et al. A two-compartment gel phantom for optimization and quality assurance in clinical BOLD fMRI
Taylor et al. NMR imaging in theory and in practice
Cuña et al. Simulated and experimental phantom data for multi-center quality assurance of quantitative susceptibility maps at 3 T, 7 T and 9.4 T
Weerakoon et al. Relative diffusion of paramagnetic metal complexes of MRI contrast agents in an isotropic hydrogel medium
Hennel et al. Basics of magnetic resonance imaging
Chan Disentangling a Cube: Imaging White Matter with Advanced MRI Techniques
Hu Development and Application of Analysis Methods for Hyperpolarized Carbon-13 Imaging for Quantitative Metabolic Characterization
US9747490B2 (en) Cell size imaging
JP2001198109A (en) Image forming method and magnetic resonance tomographic system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09822934

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13126253

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09822934

Country of ref document: EP

Kind code of ref document: A1